Document:

Camber Energy, Inc. 8-K

 

Exhibit 10.2

 

AMENDMENT
TO STOCK PURCHASE AGREEMENT

 

This
Amendment to Stock Purchase Agreement (“Amendment”) is made and entered into on March 2, 2018 (“Amendment
Date”), by and between Camber Energy, Inc., a Nevada corporation, formerly known as Lucas Energy, Inc. (“Company”),
and the investor whose name appears below (“Investor”).

Recitals

A.

On
October 5, 2017, Company and Investor entered into a Stock Purchase Agreement (“Agreement”) pursuant to which
Investor agreed to purchase shares of Series C Redeemable Convertible Preferred Stock (“Preferred”) convertible
into shares of Common Stock of Company (“Common Stock”) pursuant to a Certificate of Designations of Preferences,
Powers, Rights and Limitations of Series C Redeemable Convertible Preferred Stock filed by the Company with the Secretary of State
of Nevada on August 25, 2016 (“Certificate”).

B.

Investor
has at all times fully and completely complied with all of its obligations under the Agreement and the Certificate, and all Delivery
Notices and calculations provided to Company by Investor were and are fully correct and accurate in all respects.

C.

At
Company’s annual meeting of stockholders on January 9, 2018, stockholders authorized
Company’s board of directors to effect a reverse stock split in a ratio of between one-for-ten and one-for-fifty
(“Reverse Split”).

D.

As
an accommodation to Company and in order to help facilitate implementation of Company’s business plan, Investor is willing
to amend the agreement in accordance with the terms hereof.

E.

Certain
capitalized terms used herein, but not otherwise defined herein, have the meanings given to such terms in the Agreement and/or
the Certificate.

Agreement

In
consideration of the premises, and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged,
Company and Investor agree as follows:

1.

Waiver
of All Trigger Events. With respect to all shares of Preferred, other than any which
have already been converted prior to the Amendment Date, Investor hereby (a) waives any and all Trigger Events (as defined in
the Certificate) that have occurred prior to the Amendment Date, (b) agrees that all calculations provided for in the Certificate
shall be made as if no such Trigger Event had occurred, and (c) waives any right to receive any additional shares of Common Stock
based upon any such Trigger Event. For the avoidance of doubt, the foregoing does not apply to and shall have no effect with regard
to any Trigger Event that may occur in the future. 

2.

Common
Stock Value Increase. Notwithstanding the provisions of Section I.G.4 of the Certificate, that if Company effectuates
a reverse stock split all share based metrics will be proportionately
increased, Investor hereby (a) agrees that the $0.05 per share amount provided for in Section I.C.2 of the Certificate will not
be increased as a result of the Reverse Split, and (b) waives any right to receive any additional shares of Common Stock under
the foregoing provision based upon the Reverse Split.

    	 	1	 

    	 

    

3.

Acknowledgement.
Company hereby acknowledges and agrees that Investor has at all times fully and completely complied with all of its obligations
under the Agreement, the Certificate and all other Transaction Documents between Company and Investor, and that all Delivery Notices
and calculations provided by Investor to Company were and are fully correct and accurate in all respects.

4.

Ratification.
Except as expressly provided herein, the Agreement, which is incorporated by reference as though set forth in full herein,
and Certificate are hereby ratified and affirmed in all respects, and remain in full force and effect. Except as expressly provided
herein, the execution of this Amendment shall not operate as a waiver of any right, power or remedy of the Investor, constitute
a waiver of any provision of any of the Agreement, Certificate or any Transaction Document or serve to effect a novation of the
obligations under the Agreement, Certificate or any Transaction Document. Except as expressly provided herein, the Agreement and
all Transaction Documents between Company and Investor shall continue in full force and effect and nothing herein shall act as
a waiver of any of the Investor’s rights under any of the foregoing.

IN
WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized signatories
on the Amendment Date. 

	Company:	 
	 	 
	CAMBER
ENERGY, INC.	 
	 	 
	 	 
	By:	 	 	 
	Name:	 	 	 
	Title:	 	 	 
	 	 
	 	 
	Investor:	 
	 	 
	 	 	 
	Investor Name	 
	 	 
	 	 
	By:	 	 	 
	Name:	 	 	 
	Title:	 	 	 

 

 

 

    	 	2Exhibit 10.35

 

Confidential Materials omitted and
filed separately with the Securities and Exchange Commission. 

***Triple asterisks denote omissions.

 

	EXECUTION VERSION
	 
	LICENSE AGREEMENT
	
         

        dated

         

        FEBRUARY
        2, 2018

         

	
        among

         

        ARQULE, INC.,

         

        SINOVANT SCIENCES LTD

         

        and

         

        ROIVANT SCIENCES LTD.

 

	
        

         

        Allen & Overy

 

     

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

 

Contents

 

	Clause	 	Page
	 	 	 
	1.	Definitions	1
	2.	Grant of Rights	14
	3.	Regulatory and Commercialization Activities	17
	4.	Development Committee	24
	5.	Payments and Records	26
	6.	Intellectual Property	32
	7.	Confidentiality and Non-Disclosure	39
	8.	Representations and Warranties	43
	9.	Indemnity; Insurance	45
	10.	Term and Termination	48
	11.	Miscellaneous	52
	Schedule 1	60
	Existing Patents	60
	Schedule 2	61
	Licensed Compound	61
	Schedule 3	62
	The Initial Development Plan	62
	Schedule 4	63
	ArQule Know-How	63
	 	 
	Signatories	59

 

     

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

 

This License Agreement (this Agreement)
is made and entered into effective as of February 2, 2018 (the Effective Date)

 

BY and AMONG:

 

		(1)	ARQULE, INC, a Delaware corporation with offices at One Wall Street, Burlington, MA 01803
(ArQule);

 

		(2)	Sinovant Sciences Ltd., an exempted limited company incorporated under the laws of Bermuda,
having its registered office at 2 Church Street, Hamilton, Bermuda, and a wholly-owned subsidiary of Parent (Licensee);
and

 

		(3)	Solely for purposes of Clause 11.17 (Guaranty), Roivant Sciences Ltd., an exempted limited
company incorporated under the laws of Bermuda, having its registered office at 2 Church Street, Hamilton, Bermuda (Parent).

 

ArQule and Licensee are referred to herein
individually as a Party and collectively as the Parties.

 

RECITALS:

 

		(A)	WHEREAS, ArQule owns and Controls certain intellectual property rights with respect to the
Licensed Compound (as defined herein); and

 

		(B)	WHEREAS, ArQule wishes to grant a license to Licensee and Licensee wishes to take a license
under such intellectual property rights to develop and commercialize Licensed Products in the Territory, in each case in accordance
with the terms and conditions set forth below.

 

NOW, THEREFORE, in consideration
of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:

 

		1.	Definitions

 

Unless otherwise specifically
provided herein, the following terms shall have the following meanings:

 

AAA
has the meaning set forth in Clause 11.5 (Governing Law and Dispute Resolution).

 

Affiliate
means, with respect to a Party, any Person that, directly or indirectly, through one (1) or more intermediaries, controls, is controlled
by or is under common control with such Party. For purposes of this definition, "control" and, with correlative meanings,
the terms "controlled by" and "under common control with" means:

 

		(a)	the possession, directly or indirectly, of the power to direct the management or policies of a
business entity, whether through the ownership of voting securities, by contract relating to voting rights or corporate governance
or otherwise;

 

		(b)	the right to elect a majority of the members of the board of directors, or to appoint the chief
executive officer, general manager or other senior management officials; or

 

		(c)	the ownership, directly or indirectly, of fifty percent (50%) or more of the voting securities
or other ownership interest of a business entity (or, with respect to a limited partnership or other similar entity, its general
partner or controlling entity).

    	 	1	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Agreement
has the meaning set forth in the preamble hereto.

 

Alliance
Manager has the meaning set forth in Clause 4.2(e) (Alliance Managers).

 

Anti-Corruption
Laws has the meaning set forth in Clause 8.4 (Anti-Bribery and Anti-Corruption Compliance).

 

Applicable
Law means any laws, rules and regulations, including any rules, regulations, guidelines or other requirements of the Regulatory
Authorities, that may be in effect from time to time and applicable to a particular activity hereunder, including the FFDCA, DAL,
Provision for Drug Registration of CFDA and the Anti-Corruption Laws.

 

Arbitration
Notice has the meaning set forth in Clause 11.5 (Governing Law and Dispute Resolution).

 

Arbitrators
has the meaning set forth in Clause 11.5 (Governing Law and Dispute Resolution).

 

ArQule
has the meaning set forth in the preamble hereto.

 

ArQule Development
Data means any (a) pharmacology, toxicology and other biological data Controlled by ArQule and included in, or filed in support
of, the Regulatory Documentation filed by ArQule outside of the Territory and (b) clinical data Controlled by ArQule and included
in, or filed in support of, the Regulatory Documentation filed by ArQule outside of the Territory.

 

ArQule Fish
Assay has the meaning set forth in Clause 3.7 (Companion Diagnostics).

 

ArQule Inventions
means any Inventions, other than any Compound-Specific Inventions, that are first conceived or reduced to practice by employees
of, or consultants to, ArQule, alone or jointly with any Third Party at any time during the Term.

 

ArQule Invention
Patents means any Patents that contain one (1) or more claims that cover ArQule Inventions.

 

ArQule Know-How
means all Information Controlled by ArQule or any of its Affiliates at any time during the Term, including all ArQule Inventions
and Compound-Specific Inventions, that is (a) not generally known and (b) reasonably necessary or useful for the Exploitation of
the Licensed Compound or any Licensed Product for use in the Field and in the Territory, but excluding any Information to the extent
covered or claimed by published ArQule Patents or Joint Patents or any Joint Inventions.

 

ArQule Patents
means all of the Patents Controlled by ArQule or any of its Affiliates at any time during the Term, including all ArQule Invention
Patents and Compound-Specific Invention Patents, that are reasonably necessary or useful (or, with respect to Patent applications,
would be reasonably necessary or useful if such Patent applications were to issue as Patents) for the Exploitation of the Licensed
Compound or any Licensed Product for use in the Field and in the Territory, but excluding any Joint Patents. The ArQule Patents
include the Existing Patents.

 

ArQule Regulatory
Documentation means the Regulatory Documentation Controlled by ArQule or any of its Affiliates at any time during the Term
relating to the Compound in the Field in the Territory.

 

Assist means
providing, directly or indirectly, a Third Party with (a) any analysis of any of the ArQule Patents or any portion thereof; (b)
prior art or analysis of any prior art to any of the ArQule Patents; or (c) financial or technical or other support in connection
with a Challenge of any of the ArQule Patents or any portion thereof.

 

    	 	2	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Audit
has the meaning set forth in Clause 5.10 (Audit).

 

Auditor
has the meaning set forth in Clause 5.11 (Audit Dispute).

 

Authorized
Representative has the meaning set forth in Clause 8.4 (Anti-Bribery and Anti-Corruption Compliance).

 

Breaching
Party has the meaning set forth in Clause 10.2(a) (Termination for Convenience by Licensee).

 

Business
Day means a day other than a Saturday or Sunday or a day on which banking institutions in New York, NY or Bermuda are permitted
or required to be closed.

 

Calendar
Quarter means each successive period of three (3) calendar months commencing on 1 January, 1 April, 1 July and 1 October,
except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to
1 April and the last Calendar Quarter shall end on the last day of the Term.

 

Calendar
Year means each successive period of twelve (12) calendar months commencing on 1 January and ending on 31 December, except
that the first Calendar Year of the Term shall commence on the Effective Date and end on 31 December of the year in which the Effective
Date occurs and the last Calendar Year of the Term shall commence on 1 January of the year in which the Term ends and end on the
last day of the Term.

 

CFDA
means China Food and Drug Administration.

 

Challenge
means to contest or Assist in the contesting of the validity or enforceability of any of the ArQule Patents, in whole or in part,
in any court, arbitration proceeding or other tribunal, including the United States Patent and Trademark Office and the United
States International Trade Commission. For the avoidance of doubt, the term “contest” includes: (a) filing an action
under 28 U.S.C. §§ 2201-2202 seeking a declaration of invalidity or unenforceability of any ArQule Patents; (b) citation
to the United States Patent and Trademark Office pursuant to 35 U.S.C. § 301 of prior art patents or printed publications
or statements of the patent owner concerning the scope of any of the ArQule Patents; (c) filing a request under 35 U.S.C. §
302 for re-examination of any of the ArQule Patents; (d) filing, or joining in, a petition under 35 U.S.C. § 311 to institute
inter partes review of any ArQule Patents or any portion thereof; (e) filing, or joining in, a petition under 35 U.S.C. §
321 to institute post-grant review of the ArQule Patents or any portion thereof; (f) provoking or becoming a party to an interference
with an application for any of the ArQule Patents pursuant to 35 U.S.C. § 135; (g) filing or commencing any re-examination,
opposition, cancellation, nullity or similar proceedings against any of the ArQule Patents in any country; or (h) any foreign equivalents
of subsection (a) through (g) applicable in the Territory.

 

Change of
Control with respect to a Party means any of the following:

 

		(a)	any Person or Group (as such terms are defined below) is or becomes the Beneficial Owner (as defined
below, except that a Person or Group shall be deemed to have Beneficial Ownership of all shares of capital stock or other equity
interests if such Person or Group has the right to acquire, whether such right is exercisable immediately or only after the passage
of time), directly or indirectly, of shares of capital stock or other interests (including partnership interests) of such Party
then outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors,
managers or similar supervisory positions (Voting Stock) of such Party representing fifty percent (50%) or more of the total
voting power of all outstanding classes of Voting Stock of such Party

 

    	 	3	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(b)	such Party enters into a merger, consolidation or similar transaction with another Person (whether
or not such Party is the surviving entity) and as a result of such merger, consolidation or similar transaction the Persons
that Beneficially Owned, directly or indirectly, the shares of Voting Stock of such Party immediately prior to such transaction
cease to Beneficially Own, directly or indirectly, shares of Voting Stock of such Party representing at least a majority of the
total voting power of all outstanding classes of Voting Stock of the surviving Person in substantially the same proportions as
their ownership of Voting Stock of such Party immediately prior to such transaction;

 

		(c)	such Party sells or transfers to any Third Party, in one (1) or more related transactions, properties
or assets representing all or substantially all of such Party's consolidated total assets to which this Agreement relates;

 

		(d)	the holders of capital stock of such Party approve a plan or proposal for the liquidation or dissolution
of such Party.

 

For the purpose of this definition
of Change of Control:

 

		(i)	Person and Group have the meanings given such terms under Section 13(d) and 14(d)
of the United States Securities Exchange Act of 1934 and the term Group includes any group acting for the purpose of acquiring,
holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the aforesaid Act;

 

		(ii)	a Beneficial Owner shall be determined in accordance with Rule 13d-3 under the aforesaid
Act; and

 

		(iii)	the terms Beneficially Owned and Beneficially Own shall have meanings correlative
to that of Beneficial Owner

 

For clarity,
any investment transaction by venture capital or other financial investors not engaged directly in the pharmaceutical or biotechnology
business and not otherwise affiliated with a pharmaceutical or biotechnology company, the purpose of which is to raise capital
for a Party, shall not be deemed to be a Change of Control of that Party.

 

Combination
Product means a Licensed Product that is comprised of or contains the Licensed Compound as an active ingredient together with
one (1) or more other active ingredients and is sold either as a fixed dose or as separate doses in a single package.

 

Commercialization
means any and all activities directed to the preparation for sale, offering for sale, or sale of a Licensed Product, including
activities related to marketing, advertising, promoting, distributing (including without limitation importing, exporting, transporting,
customs clearance, warehousing, invoicing, handling and delivering the Licensed Product to customers), using and selling such Licensed
Product, and booking sales, and interacting with Regulatory Authorities regarding any of the foregoing. When used as a verb, to
Commercialize and Commercializing means to engage in Commercialization and Commercialized has a corresponding
meaning.

 

Commercial
Milestone Event has the meaning set forth in Clause 5.3 (Commercial Milestones).

 

Commercially
Reasonable Efforts means, with respect to the performance of Development, Manufacturing, and Commercialization activities with
respect to the Licensed Compound or a Licensed Product by Licensee, the carrying out of such activities using efforts and resources
comparable to the efforts and resources commonly used in the biopharmaceutical industry by companies with resources and expertise
comparable to those of Parent for internally-developed compounds or products of similar market potential at a similar stage in
development or product life.

 

    	 	4	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Confidential
Information has the meaning set forth in Clause 7.1 (Confidentiality Obligations).

 

Commercialization
Plan means the commercialization plan for the Licensed Product in the Field in the Territory, as such plan may be amended or
updated from time to time in accordance with this Agreement. The Commercialization Plan will include in reasonable detail (a) a
multi-year marketing and distribution plan, including a timeline for such activities, the estimated launch date in the Territory
and Licensee’s principal strategies with respect to marketing, distributing and promoting the Licensed Product during the
applicable time period, (b) the material activities to be conducted by Licensee in connection with the Commercialization of the
Licensed Product during such time period, (c) a five (5) year sales forecast for the Licensed Product in the Territory.

 

Compound-Specific
Invention means any Invention that (a) relates to the composition of matter, and/or use of the Licensed Compound (including
any derivative, analog or modification thereof) and/or (b) directly relates to the Manufacture of the Licensed Compound (including
any derivative, analog or modification thereof) and does not relate generally to the manufacture of any other compound, in any
case whether or not patented or patentable.

 

Compound-Specific
Invention Patent means any Patent that contains one (1) or more claims that cover any Compound-Specific Invention.

 

Control
means, with respect to any item of Information, Regulatory Documentation, material, Patent or other intellectual property right,
possession of the right, whether directly or indirectly and whether by ownership, license or otherwise (other than by operation
of the license and other grants in Clause 2.1 (Grants to Licensee) or 2.2 (Grants to ArQule)), to grant a license, sublicense or
other right (including the right to reference Regulatory Documentation) to or under such Information, Regulatory Documentation,
material, Patent or other intellectual property right as provided for herein without violating the terms of any agreement with
any Third Party. For clarity, no Party (or an Affiliate of a Party, as applicable) shall be deemed to Control any Information,
Regulatory Documentation, material, Patent or other intellectual property right by virtue of the license grants to that Party from
or by the other Party as set forth in this Agreement.

 

Controlling
Party has the meaning set forth in Clause 6.5 (Invalidity or Unenforceability Defenses or Actions).

 

Corporate
Names means any Trademarks, names and logos Controlled by ArQule at any time during the Term.

 

CTA means
a Clinical Trial Application that is required to initiate a clinical trial for registering a drug product under Chinese Drug Administration
Law and Provisions for Drug Registration (CFDA Order. 28) or equivalence thereof under the future Chinese laws and rules, as the
same may be amended from time to time.

 

DAL
means Chinese Drug Administration Law.

 

Development
means, with respect to the Licensed Compound and any Licensed Product, all activities related to research, pre-clinical and other
non-clinical testing, test method development and stability testing, toxicology, formulation, process development, manufacturing
scale-up, qualification and validation, quality assurance/quality control, clinical studies, including Manufacturing in support
thereof, statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs
with respect to the foregoing and all other activities necessary or reasonably useful or otherwise requested or required by a Regulatory
Authority as a condition or in support of obtaining or maintaining a Regulatory Approval for such Licensed Compound or Licensed
Product. When used as a verb, Develop means to engage in Development.

 

    	 	5	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Development
Plan means the plan for the Development of the Licensed Compound for Regulatory Approvals and Post-Approval Development in
the Territory, including in reasonable detail (a) all material Development activities reasonably anticipated to be undertaken by
Licensee to obtain Regulatory Approval of a Licensed Product in the Field in the Territory, (b) a high level summary of the design
for all clinical trials involving the Licensed Product, (c) estimated dates on which Licensee expects to achieve each Development
Milestone Event, and (d) an estimate of costs and expenses associated with the activities set forth therein, as such plan may be
amended or updated from time to time in accordance with this Agreement. For clarity, the Initial Development Plan is attached hereto
as Schedule 3 and such Initial Development Plan shall be amended, modified or updated solely in accordance with this Agreement.

 

Dispute
has the meaning set forth in Clause 11.5 (Governing Law and Dispute Resolution).

 

Dollars
or $ means United States Dollars.

 

Drug Approval
Application means, with respect to any Licensed Product in any country in the Territory, an application for Regulatory Approval
for such Licensed Product in such country, including: (a) an NDA, or any future equivalent thereto as defined in the DAL and the
Provisions for Drug Registration, (b) any corresponding foreign application in any other country in the Territory; and (c) all
renewals, supplements and amendments to any of the foregoing.

 

Effective
Date has the meaning set forth in the preamble hereto.

 

Enforcing
Party has the meaning set forth in Clause 6.3(b) (Enforcement of Patents).

 

Existing
Patents means the Patents listed on Schedule 1.

 

Exploit
means to make, have made, import, use, sell or offer for sale, including to research, Develop, Commercialize, register, Manufacture,
have Manufactured, hold or keep (whether for disposal or otherwise), have used, export, transport, distribute, promote, market
or have sold or otherwise dispose of. Exploitation means the act of Exploiting a compound, product or process.

 

FDA
means the United States Food and Drug Administration and any successor agency thereto.

 

FFDCA
means the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time, together with any rules, regulations
and requirements promulgated thereunder (including all additions, supplements, extensions and modifications thereto).

 

Field
means all therapeutic uses in humans and animals.

 

FGFR means
all Fibroblast Growth Factor Receptors including Fibroblast growth factor receptor 1, Fibroblast growth factor receptor 2, Fibroblast
growth factor receptor 3, Fibroblast growth factor receptor 4 and all their isoforms.

 

First Commercial
Sale means, with respect to a Licensed Product in any country in the Territory, the first sale for monetary value for use or
consumption by the end user of such Licensed Product in such country after Regulatory Approval for such Licensed Product has been
obtained in such country. Sales prior to receipt of Regulatory Approval for such Licensed Product, such as so-called "treatment
IND sales," "named patient sales," and "compassionate use sales," shall not be construed as a First Commercial
Sale.

 

FPFV
means the first patient's first screening visit in a clinical trial at or prior to which such subject signs an informed consent
to participate in such clinical trial.

 

    	 	6	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

GAAP
means current United States generally accepted accounting principles, International Financial Reporting Standards or such other
similar national standards as a Party, its Affiliates or its or their sublicense adopts, in each case, consistently applied.

 

Generic
Product means, with respect to a particular mode of administration of a Licensed Product, any other prescription pharmaceutical
product that (a) contains the same active ingredient(s) as such Licensed Product, (b) has the same mode of administration as such
Licensed Product and (c) is "therapeutically equivalent" as evaluated by the FDA, applying the definition of "therapeutically
equivalent" to such Licensed Product set forth in the preface to the FDA's Orange Book (or, with respect to any country in
the Territory outside the United States, is similarly substitutable under equivalent Applicable Law), such that the pharmaceutical
product may be substituted for the Licensed Product at the point of dispensing without any intervention by the prescribing physician
in such country.

 

Government
Official means (a) any Person employed by or acting on behalf of a government, government-controlled agency or entity or public
international organization, (b) any political party, party official or candidate, (c) any Person who holds or performs the duties
of an appointment, office or position created by custom or convention or (d) any Person who holds himself out to be the authorized
intermediary of or has a close relationship with any of the foregoing who can reasonably influence foregoing’s decision making,
including, but not limited to, the direct relatives of foregoing.

 

Hatch-Waxman
Act means the U.S. "Drug Price Competition and Patent Term Restoration Act" of 1984, as set forth at 21 U.S.C. §355(b)(2)(A)(iv)
or (j)(2)(A)(vii)(IV).

 

IDL
means an imported drug license under the Chinese DAL and its relevant regulation and rules.

 

Invention
means any Information (including any new and useful process, method of manufacture, chemical composition or composition of matter)
that is first conceived and reduced to practice (actually or constructively), whether or not patentable, by or on behalf of either
Party, or jointly by the Parties, in connection with the conduct of the Development activities and/or the Exploitation of the Licensed
Compound or any Licensed Product.

 

IND
means (a) an investigational new drug application filed with the FDA for authorization to commence clinical studies and its
equivalent in other countries or regulatory jurisdictions and (b) all supplements and amendments that may be filed with respect
to the foregoing.

 

Indemnification
Claim Notice has the meaning set forth in Clause 9.3(a) (Notice of Claim).

 

Indemnified
Party has the meaning set forth in Clause 9.3(a) (Notice of Claim).

 

Information
means all technical, scientific and other know-how and information, trade secrets, knowledge, technology, means, methods, processes,
practices, formulae, instructions, skills, techniques, procedures, experiences, ideas, technical assistance, designs, drawings,
assembly procedures, computer programs, apparatuses, specifications, data, results and other material, including: biological, chemical,
pharmacological, toxicological, pharmaceutical, physical and analytical, pre-clinical, clinical, safety, manufacturing and quality
control data and information, including study designs and protocols, assays and biological methodology, in each case (whether or
not confidential, proprietary, patented or patentable) in written, electronic or any other form now known or hereafter developed.

 

Infringement
has the meaning set forth in Clause 6.3(a) (Notice).

 

Initial
Development Plan has the meaning set forth in Clause 3.1(a) (Development Plan).

 

    	 	7	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Invoiced
Sales has the meaning set forth in the definition of Net Sales.

 

Joint Intellectual
Property Rights has the meaning set forth in Clause 6.1(b) (Ownership of Joint Patents and Joint Inventions).

 

Joint Inventions
has the meaning set forth in Clause 6.1(b) (Ownership of Joint Patents and Joint Inventions).

 

Joint Patents
has the meaning set forth in Clause 6.1(b) (Ownership of Joint Patents and Joint Inventions).

 

Joint Development
Committee or JDC has the meaning set forth in Clause 4.1(Joint Development Committee).

 

JDC Dispute
has the meaning set forth in Clause 11.5 (Governing Law and Dispute Resolution).

 

Knowledge
means the actual knowledge without any duty to conduct any investigation with respect to such facts and information.

 

Licensed
Compound means (a) the pharmaceutical compound described on Schedule 2 attached hereto, (b) *** and (c) any metabolite, salt,
ester, anhydrides, hydrate, solvate, isomer, enantiomer, free acid form, free base form, crystalline form, co-crystalline form,
amorphous form, pro-drug (including ester pro-drug) form, racemate, polymorph, chelate, stereoisomer, tautomer or optically active
form of any of the foregoing.

 

Licensed
Product means any biological, pharmaceutical or therapeutic compound, substance, chemical composition or formulation that contains,
incorporates or comprises the Licensed Compound alone or in combination with one (1) or more other active ingredients, in any and
all forms, presentations, dosages and formulations of such Licensed Compound.

 

Licensed
Product Agreement means, with respect to a Licensed Product, any agreement entered into by and between Licensee or any of its
Affiliates or its or their Sublicensees, on the one hand, and one (1) or more Third Parties, on the other hand, during the Term
that is necessary or reasonably useful for the Exploitation of such Licensed Product in the Field in the Territory, including (a)
any agreement pursuant to which Licensee, its Affiliates or its or their Sublicensees receives any license or other rights to Exploit
such Licensed Product, (b) supply agreements pursuant to which Licensee, its Affiliates or its or their Sublicensees obtain or
will obtain quantities of such Licensed Product, (c) clinical trial agreements, (d) contract research organization agreements and
(e) service agreements.

 

Licensee
has the meaning set forth in the preamble hereto.

 

Licensee
Development Data means any (a) pharmacology, toxicology and other biological data included in or in support of the Regulatory
Documentation in the Territory that was created by Licensee or on behalf of Licensee or by a Third Party and (b) clinical data
included in or in support of Regulatory Documentation in the Territory.

 

Licensee
Inventions means any Inventions, other than any Compound-Specific Inventions, that are first conceived or reduced to practice
by employees of, or consultants to, Licensee, alone or jointly with any Third Party at any time during the Term.

 

Licensee
Invention Patents means any Patents that contain one (1) or more claims that cover Licensee Inventions.

 

    	 	8	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Licensee
Know-How means all Information Controlled by Licensee or any of its Affiliates at any time during the Term that is (a) not
generally known and (b) reasonably necessary or useful for the Exploitation of the Licensed Compound or any Licensed Product, but
excluding any Information to the extent covered or claimed by published Licensee Patents or Joint Patents or any Joint Inventions.
For clarity, Licensee Know-How shall not include Compound-Specific Inventions.

 

Licensee
Patents means all Patents that claim or cover any Licensee Know-How, but excluding any Joint Patents.

 

Licensee
Regulatory Documentation means the Regulatory Documentation Controlled by Licensee or any of its Affiliates as of the Effective
Date relating to the Compound in the Field in the Territory.

 

LML
means a local manufacture license under the Chinese DAL and its relevant regulation and rules.

 

Losses
has the meaning set forth in Clause 9.1 (Indemnification of ArQule).

 

MAH
means an official document authorizing a market authorization holder for a Licensed Product under the Chinese DAL and its relevant
regulation and rules.

 

Manufacture
and Manufacturing means all activities by or on behalf of a Party related to the production, manufacture, processing, filling,
finishing, packaging, labelling, in-process and finished testing, shipping, storing, or release of a product or any ingredient
or intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical, clinical
and commercial manufacture and analytic development, product characterization, test method development and stability testing, formulation,
quality assurance and quality control of the Licensed Compound or any Licensed Product, and regulatory activities related to any
of the foregoing.

 

NDA means
a New Drug Application, as defined in the FFDCA and regulations promulgated thereunder, or any successor application or procedure
required to sell a Licensed Product in the United States.

 

Net Sales
means, with respect to a Licensed Product for any period, the gross amount billed or invoiced by Licensee, its Affiliates or its
or their Sublicensees (other than Third Party distributors) to Third Parties (including Third Party distributors) for the sale
of a Licensed Product (the Invoiced Sales), less deductions for:

 

		(a)	normal and customary trade, quantity and prompt settlement discounts (including chargebacks and
allowances) actually taken off the invoiced price;

 

		(b)	amounts repaid or credited, retroactive or otherwise, as rebates or by reason of rejection, return
or recall of Licensed Products;

 

		(c)	transportation, importation, freight, postage, shipping, insurance and other handling expenses
to the extent that such items are included in the gross amount invoiced and separately identified;

 

		(d)	customs and excise duties, sales taxes, value added taxes (but excluding income taxes imposed on
net income) and other similar taxes and duties actually paid or incurred with respect to the Licensed Product;

 

		(e)	government-mandated price reductions or rebates applicable to any Licensed Product such as, by
way of illustration and not in limitation of the Parties' rights hereunder, Federal or state Medicaid, Medicare or similar state
program or equivalent foreign governmental program;

 

    	 	9	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(f)	the portion of any management or administrative fees paid during the relevant time period to government
payor health care programs, group purchasing organizations or pharmaceutical benefit managers relating to such Licensed Product;
and

 

		(g)	amounts invoiced for sales of Licensed Product that are written off as uncollectible after reasonable
collection efforts, in accordance with GAAP and standard practices of Licensee, its Affiliates or its or their Sublicensees; provided,
that such write-offs shall be capped at three percent (3%) of gross amounts invoiced for Licensed Product sold in the applicable
Calendar Quarter.

 

Any of the deductions listed
above that involves a payment by Licensee, its Affiliates or its or their Sublicensees shall be taken as a deduction in the Calendar
Quarter in which the payment is accrued by such entity. A particular deduction may only be accounted for once in the calculation
of Net Sales. For purposes of determining Net Sales, a Licensed Product shall be deemed to be sold when invoiced and a sale shall
not include transfers or dispositions of such Licensed Product for pre-clinical or clinical purposes or as samples or through patient
assistance programs, in each case, without charge. Licensee's, its Affiliates' or its or their Sublicensees' transfer of any Licensed
Product to an Affiliate or Sublicensee shall not result in any Net Sales, unless such Licensed Product is consumed or administered
by such Affiliate or Sublicensee in the course of its commercial activities. With respect to any Licensed Product that is consumed
or administered by Licensee or its Affiliates or its or their Sublicensees, Net Sales shall include any amount billed or invoiced
with respect to such consumption or administration, including any services provided directly in connection therewith.

 

In the event that a Licensed
Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product shall be adjusted by
multiplying actual Net Sales of such Combination Product in such country calculated pursuant to the foregoing definition of Net
Sales by the fraction A/(A+B), where A is the average invoice price in such country of any Licensed Product that contains the same
Licensed Compound(s) as such Combination Product as its sole active ingredient(s), if sold separately in such country and B is
the average invoice price in such country of each product that contains active ingredient(s) other than the Licensed Compound(s)
contained in such Combination Product as its sole active ingredient(s), if sold separately in such country.

 

In the event that the weighted
average sale price of a Licensed Product can be determined but the weighted average sale price of the other active compound or
ingredient in the Combination Product cannot be determined, then Net Sales for such product shall be calculated by multiplying
the net sales of the Combination Product (as calculated in accordance with analogous criteria as set forth above for the “Net
Sales” definition) by the fraction A/C where A is the weighted average sale price of such Licensed Product when sold separately
in finished form and C is the weighted average sale price of the Combination Product.

 

In the event that the weighted
average sale price of the other active compounds or ingredients in the Combination Product can be determined but the weighted average
sale price of such Licensed Product cannot be determined, Net Sales for such product shall be calculated by multiplying the net
sales of the Combination Product (as calculated in accordance with analogous criteria as set forth above for the “Net Sales”
definition) by the following formula: one (1) minus B / C where B is the weighted average sale price of the other active compound
or ingredient in the Combination Product when sold separately in finished form and C is the weighted average sale price of the
Combination Product.

 

In the event that the weighted
average sale price of both a Licensed Product and the other active compound or ingredient in the Combination Product cannot be
determined in a country, then, the Parties shall negotiate in good faith a reasonable adjustment to Net Sales in such country that
takes into account all factors reasonably relevant to the relative value of the Licensed Compound(s), on the one hand, and all
of the other active ingredient(s), collectively, on the other hand.

 

    	 	10	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

In the case of pharmacy incentive
programs, hospital performance incentive programs, chargebacks, disease management programs, similar programs or discounts on portfolio
product offerings, all rebates, discounts and other forms of reimbursements shall be allocated among products on the basis on which
such rebates, discounts and other forms of reimbursements were actually granted or, if such basis cannot be determined, in accordance
with Licensee's, its Affiliates' or its or their Sublicensees' existing allocation method; provided that any such allocation
to a Licensed Product shall be: (i) done in accordance with Applicable Law, including any price reporting laws, rules and regulations
and (ii) subject to Clause (i), in no event no greater than a pro rata allocation, such that the portion of each of the foregoing
rebates, discounts and other forms of reimbursements shall not be included as deductions from Invoiced Sales hereunder in any amount
greater than the proportion of the number of units of such Licensed Product sold by Licensee, its Affiliates or its or their Sublicensees
to Third Parties hereunder compared to the number of units of all the products sold by Licensee, such Affiliates and such Sublicensees
to Third Parties to which such foregoing rebate, discount or other form of reimbursement, as applicable, are granted.

 

Subject to the above, Net Sales
shall be calculated in accordance with the standard internal policies and procedures of Licensee, its Affiliates or its or their
Sublicensees, which must be in accordance with GAAP.

 

Non-Breaching
Party has the meaning set forth in Clause 10.2(a) (Material Breach).

 

Notice Period
has the meaning set forth in Clause 10.2(a) (Material Breach).

 

Party
and Parties has the meaning set forth in the preamble hereto.

 

Patents
means:

 

		(a)	all national, regional and international patents and patent applications, including provisional
patent applications;

 

		(b)	all patent applications filed either from such patents, patent applications or provisional applications
or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals,
converted provisionals and continued prosecution applications;

 

		(c)	any and all patents that have issued or in the future issue from the foregoing patent applications
((a) and (b)), including utility models, petty patents, invention patents and design patents and certificates of invention;

 

		(d)	any and all extensions or restorations by existing or future extension or restoration mechanisms,
including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates and the
like) of the foregoing patents or patent applications ((a), (b) and (c)); and

 

		(e)	any similar rights, including so-called pipeline protection or any importation, revalidation, confirmation
or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents.

 

Payment
has the meaning set forth in Clause 5.7(a) (General).

 

    	 	11	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

 

Person
means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited
liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity
or organization, including a government or political subdivision, department or agency of a government.

 

Post-Approval
Development means ongoing development of a Licensed Product after such Licensed Product has received Regulatory Approval in
the Territory, including phase IV clinical studies and clinical studies in support of indications within the Field or labelling
changes for such Licensed Product within the Field in the Territory during the Term.

 

Product
Trademarks means the Trademark(s) used or to be used by Licensee or its Affiliates or its or their Sublicensees for the Commercialization
of Licensed Products in the Field and in the Territory and any registrations thereof or any pending applications relating thereto
in the Territory (excluding, in any event, any Corporate Names and any Trademarks that consist of or include any corporate name
or corporate logo of ArQule or its Affiliates or its or their (sub)licensees (or Sublicensees)).

 

Prohibited
Payment has the meaning set forth in Clause 8.4 (Anti-Bribery and Anti-Corruption Compliance).

 

Prosecuting
Party has the meaning set forth in Clause 6.2(a) (In General).

 

Regulatory
Approval means, with respect to a country in the Territory, any approvals or authorizations of any Regulatory Authority necessary
to commercially distribute, sell or market a Licensed Product in such country. For purposes of clarity, Regulatory Approval in
China will include any IDL, MAH or LML.

 

Regulatory
Authority means any applicable supra-national, federal, national, regional, state, provincial or local regulatory agencies,
departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect
to the Exploitation of Licensed Compound or Licensed Products in the Territory, including the CFDA.

 

Regulatory
Documentation means: all (a) applications (including all INDs, CTAs, Drug Registration Application and Drug Approval Applications),
registrations, licenses, authorizations and approvals (including Regulatory Approvals); (b) correspondence and reports submitted
to or received from Regulatory Authorities (including minutes and official contact reports relating to any communications with
any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint files;
and (c) clinical and other data contained or relied upon in any of the foregoing; in each case ((a), (b) and (c)) relating
to the Licensed Compound or a Licensed Product.

 

Regulatory
Exclusivity Period means, with respect to each Licensed Product in any country in the Territory, any period of data, market
or other regulatory exclusivity (other than Patent exclusivity) granted or afforded by Applicable Law or by a Regulatory Authority
in such country that confers exclusive marketing rights with respect to such Licensed Product in such country or prevents another
party from using or otherwise relying on any data supporting the approval of the NDA without the prior written consent of the NDA-holder,
as applicable.

 

Regulatory
Milestone Event has the meaning set out in Clause 5.2 (Regulatory Milestones).

 

Retained
Rights means, with respect to the Licensed Compound and Licensed Products, the rights of ArQule, its Affiliates and its and
their licensors, (sub)licensees and contractors to:

 

		(a)	perform its and their obligations under this Agreement;

 

    	 	12	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(b)	Manufacture and Develop the Licensed Compound or Licensed Products within the Territory solely
for Exploitation outside the Territory; and

 

		(c)	Exploit the Licensed Compound or Licensed Products for any and all purposes outside the Territory.

 

Royalty
Term means, with respect to each Licensed Product and each country in the Territory, the period beginning on the date of the
First Commercial Sale of such Licensed Product in such country and ending on the latest to occur of:

 

		(a)	the expiration of the last-to-expire ArQule Patent, Joint Patent or Licensee Patent, in such country
that contains a Valid Claim that claims the Licensed Compound included in such Licensed Product;

 

		(b)	the expiration of the Regulatory Exclusivity Period in such country for such Licensed Product;
and

 

		(c)	the *** anniversary of the First Commercial Sale of such Licensed Product in such country.

 

Senior Officer
means, with respect to ArQule, its Chief Executive Officer and with respect to Licensee, its Chief Executive Officer.

 

Sublicensee
means a Person, other than an Affiliate, that is granted a sublicense by Licensee or its Affiliate under the grants in Clause 2.1
(Grants to Licensee), as provided in Clause 2.3 (Sublicenses).

 

Term
has the meaning set forth in Clause 10.1 (Term and Expiration).

 

Termination
Notice has the meaning set forth in Clause 10.2(a) (Material Breach).

 

Territory
means mainland People's Republic of China, the Hong Kong Special Administrative Region, the Macau Special Administrative Region
and Taiwan.

 

Third Party
means any Person other than ArQule, Licensee and their respective Affiliates.

 

Third Party
Claims has the meaning set forth in Clause 9.1 (Indemnification of ArQule).

 

Third Party
Infringement Claim has the meaning set forth in Clause 6.4 (Infringement Claims by Third Parties).

 

Trademark
means any word, name, symbol, color, shape, designation or any combination thereof, including any trademark, service mark, trade
name, brand name, sub-brand name, trade dress, product configuration rights, program name, delivery form name, certification mark,
collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source, origin or quality,
whether or not registered, and all statutory and common law rights therein and all registrations and applications therefor, together
with all goodwill associated with, or symbolized by, any of the foregoing.

 

Transfer
Confirmation Notice has the meaning set forth in Clause 3.5(b)(iv) (Transfer Completion Notice).

 

Transfer
Completion Notice has the meaning set forth in Clause 3.5(b)(iv) (Transfer Completion Notice).

 

    	 	13	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Unanimous
Decision means any decision with respect to: (a) any material change to the scope of the Initial Development Plan; (b) any
change to the Development or regulatory strategy for the Licensed Compound or Licensed Product that would reasonably be expected
to have a material adverse effect on the Development or Commercialization of such Licensed Compound or Licensed Product in the
Territory and (c) any proposed Development activities of Licensee with respect to any Licensed Compound or Licensed Product that
would reasonably be expected to have a material adverse effect on such Licensed Compound or Licensed Product outside the Territory.

 

Valid Claim
means (a) a claim of any issued and unexpired Patent whose validity, enforceability or patentability has not been affected by (i) irretrievable
lapse, abandonment, revocation, dedication to the public or disclaimer or (ii) a holding, finding or decision of invalidity,
unenforceability or non-patentability by a court, governmental agency, national or regional patent office or other appropriate
body that has competent jurisdiction, such holding, finding or decision being final and unappealable or unappealed within the time
allowed for appeal or (b) a claim of a pending Patent application that was filed and is being prosecuted in good faith, has not
been abandoned or finally disallowed without the possibility of appeal or re-filing of the application, and has not been pending
for more than five (5) years.

 

VAT
has the meaning set forth in Clause 5.7(b) (Value Added Tax).

 

Voting Stock
has the meaning set forth in the definition of Change of Control.

 

		2.	Grant of Rights

 

		2.1	Grants to Licensee

 

Subject to
Clauses 2.3 (Sublicenses), 2.4 (Rights of Reference) and 2.5 (Retention of Rights; Limitations Applicable to License Grants) and
the other terms and conditions of this Agreement, ArQule hereby grants to Licensee an exclusive (including with regard to ArQule
and its Affiliates) license, with the right to grant sublicenses through multiple tiers in accordance with Clause 2.3 (Rights
of Reference), under the ArQule Patents, ArQule Inventions, ArQule Know-How, and ArQule's interests in Joint Patents and Joint
Inventions, to Exploit the Licensed Compound and Licensed Products in the Field in the Territory.

 

		2.2	Grants to ArQule

 

Licensee hereby grants to ArQule
a non-exclusive, royalty-free license, with the right to grant sublicenses through multiple tiers, under the Licensee Patents,
Licensee Invention Patents, Licensee Know-How, Licensee Inventions and Licensee's interests in Joint Patents and Joint Inventions,
to Exploit the Licensed Compound and Licensed Products outside the Territory and/or to perform or exercise the Retained Rights.

 

		2.3	Sublicenses

 

The Parties shall have the right
to grant sublicenses through multiple tiers, under the licenses granted in Clause 2.1 (Grants to Licensee) and 2.2 (Grants to ArQule),
respectively, to its Affiliates and other Persons; provided, that, any such sublicenses shall be: (a) subject to a Party’s
(i) providing prior written notice of any such proposed Third Party sublicense to the other Party and (ii) providing the other
Party with a copy of each fully executed Third Party sublicense agreement promptly upon execution,
in both instances with financial and other sensitive terms redacted to the extent not necessary to confirm Licensee’s compliance
with the terms of this Agreement, and (b) consistent with, and expressly made subject to, the terms and conditions of this
Agreement. Each Party shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement as if such
Sublicensee were a Party to this Agreement. No such permitted sublicense shall relieve the granting Party of any of its obligations
or liabilities hereunder, for which obligations and liabilities the granting Party shall remain fully responsible and liable.

 

    	 	14	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		2.4	Rights of Reference

 

		(a)	ArQule hereby grants to Licensee a Right of Reference, as that term is defined in 21 C.F.R. §
314.3(b) and any foreign counterpart to such regulation (and any current or future Sublicensee of Licensee of the Licensed Compound
and/or any Licensed Products) to a right of access to and a right to use and incorporate all Regulatory Documentation and the ArQule
Development Data to the extent Controlled by ArQule and necessary or useful to Develop, Manufacture, obtain Regulatory Approval
of, and Commercialize the Licensed Compound or any Licensed Product in the Territory, in each case, pursuant to the Development
Plan or Commercialization Plan and otherwise subject to the terms and conditions of this Agreement. ArQule will use commercially
reasonable efforts to have its current or future licensees of the Licensed Compound and/or any Licensed Products provide a Right
of Reference to, a right of access to and a right to use and incorporate all Regulatory Documentation controlled by such licensee
and necessary or useful to obtain Regulatory Approval of the Licensed Compound or any Licensed Product in the Territory.

 

		(b)	Without any additional consideration to Licensee, Licensee hereby grants to ArQule (and any current
or future licensee of ArQule of the Licensed Compound and/or any Licensed Products) a Right of Reference to, a right of access
to and a right to use and incorporate all Regulatory Documentation and the Licensee Development Data to the extent Controlled by
Licensee, its Affiliates and its and their licensors, (sub)licensees and contractors and necessary or useful to (i) Develop and
Manufacture the Licensed Compound and any Licensed Products inside the Territory in order to obtain Regulatory Approval of and
Commercialize the Licensed Compound and any Licensed Products outside of the Territory, and (ii) Develop, Manufacture, obtain Regulatory
Approval of, and Commercialize the Licensed Compound and any Licensed Products outside of the Territory, in each case ((i) and
(ii)) in accordance with any applicable terms and conditions of this Agreement.

 

		(c)	Each Party will provide a signed statement to this effect, if requested by the other Party, in
accordance with 21 C.F.R. § 314.50(g)(3) or any foreign counterpart to such regulation, in the case of a request by either
Party, for the limited purpose described in this Clause 2.4 (Rights of Reference). For the avoidance of doubt, neither Party may
publish or otherwise publicly disclose any data of the other Party to which a Right of Reference is granted under this Clause 2.4
(Rights of Reference) except in accordance with this Agreement. For clarity, submission of data to a Regulatory Authority shall
not be considered publication or public disclosure under the preceding sentence.

 

		(d)	In the event that Licensee discontinues Development of any Licensed Product in the Territory, then
Licensee shall (i) return all ArQule Development Data to ArQule as well as any Licensee Development Data generated by Licensee
related directly to the discontinued Licensed Product (ii) transfer to ArQule (and/or any current or future licensee of ArQule
of the Licensed Compound and/or any Licensed Products) all of its right, title and interest in all Regulatory Documentation and
Regulatory Approvals in the Territory in its name applicable to the Licensed Product; (iii) provide ArQule (and/or any current
or future licensee of ArQule of the Licensed Compound and/or any Licensed Products) with copies of all correspondence with Regulatory
Authorities relating to such Regulatory Documentation and Regulatory Approvals; and (iv) transfer sponsorship and Control to ArQule
(and/or any current or future licensee of ArQule of the Licensed Compound and/or any Licensed Products) of all clinical trials
of the Licensed Product being conducted as of the effective date of termination.

 

    	 	15	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		2.5	Retention of Rights; Limitations Applicable to License Grants

 

		(a)	Retained Rights of ArQule

 

Notwithstanding anything to the
contrary in this Agreement and without limitation of any rights granted or reserved to ArQule pursuant to any other term or condition
of this Agreement, ArQule hereby expressly retains, on behalf of itself and its Affiliates (and on behalf of its and their licensors,
(sub)licensees and contractors) all right, title and interest in and to the ArQule Patents, the ArQule Know-How, ArQule's interests
in and to Joint Patents and Joint Inventions, ArQule Regulatory Documentation with respect to any Licensed Compound or Licensed
Product and ArQule's Corporate Names, in each case, for purposes of performing or exercising the Retained Rights.

 

		(b)	No Other Rights Granted by ArQule

 

Except as expressly provided
herein and without limiting the foregoing, ArQule grants no other right or license, including any rights or licenses to the ArQule
Patents, the ArQule Know-How, ArQule Development Data, ArQule's interest in the Joint Patents and the Joint Inventions, the ArQule
Regulatory Documentation, the ArQule Corporate Names or any other Patent, Trademark or other intellectual property rights not otherwise
expressly granted herein.

 

(c)       No
Other Rights Granted by Licensee

 

Except as expressly provided
herein, Licensee grants no other right or license, including any rights or licenses to the Licensee Patents, the Licensee Know-How,
Licensee Development Data, Licensee’s interest in the Joint Patents and the Joint Inventions, or any other Patent, Trademark
or other intellectual property rights not otherwise expressly granted herein.

 

		2.6	Territorial Restrictions

 

		(a)	Licensee shall not, and shall not permit any of its Affiliates or any of its and their licensees,
Sublicensees or distributors to knowingly distribute, market, promote, offer for sale or sell the Licensed Products directly or
indirectly (i) to any Person for commercial use outside the Territory or (ii) to any Person in the Territory that Licensee or any
of its Affiliates or any of its or their licensees, Sublicensees or distributors knows (A) is likely to distribute, market, promote,
offer for sale or sell any Licensed Product for commercial use outside the Territory or Assist another Person to do so, or (B)
has directly or indirectly distributed, marketed, promoted, offered for sale or sold any Licensed Product for commercial use outside
the Territory or Assisted another Person to do so. If Licensee or any of its Affiliates receives or becomes aware of the receipt
by a licensee, Sublicensee or distributor of any orders for any Licensed Product for use outside the Territory, such Person shall
refer such orders to ArQule. Licensee shall cause its Affiliates and its and their licensees, Sublicensees and distributors to
notify ArQule of any receipt of any orders for any Licensed Product for use outside the Territory.

 

		(b)	ArQule shall not, and shall not permit any of its Affiliates or any of its and their (sub)licensees
or distributors to knowingly distribute, market, promote, offer for sale or sell the Licensed Products directly or indirectly (i)
to any Person for commercial use in the Territory or (ii) to any Person outside the Territory that ArQule or any of its Affiliates
or any of its or their (sub)licensees or distributors knows (A) is likely to distribute, market, promote, offer for sale or sell
any Licensed Product for commercial use in the Territory or Assist another Person to do so, or (B) has directly or indirectly distributed,
marketed, promoted, offered for sale or sold any Licensed Product for commercial use in the Territory or Assisted another Person
to do so. If ArQule or any of its Affiliates receives or becomes aware of the receipt by a (sub)licensee or distributor of any
orders for any Licensed Product for commercial use in the Territory, such Person shall refer such orders to Licensee. ArQule shall
cause its Affiliates to notify Licensee of any receipt of any orders for any Licensed Product for commercial use in the Territory.

 

    	 	16	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		2.7	Non-Compete

 

During the Term of this Agreement,
Licensee shall not, directly or indirectly, conduct, have conducted, Exploit, or fund any activity that involves the conduct of,
any research, development, manufacturing, importing, commercialization or Exploitation of any FGFR inhibitor in the Territory other
than pursuant to this Agreement.

 

		2.8	Section 365(n)

 

All rights and licenses granted
under or pursuant to this Agreement by Licensee or ArQule are, and will otherwise be deemed to be, for purposes of Section 365(n)
of the U.S. Bankruptcy Code, licenses of rights to "intellectual property" as defined under Section 101 of the U.S. Bankruptcy
Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, will retain and may fully exercise
all of their rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement
of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code, the Party hereto that is not a party to such
proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and
all embodiments of such intellectual property, and same, if not already in their possession, will be promptly delivered to them
(a) upon any such commencement of a bankruptcy proceeding upon their written request therefor, unless the Party subject to such
proceeding elects to continue to perform all of its obligations under this Agreement, or (b) if not delivered under (a) above,
following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefor
by the non-subject party.

 

		3.	Regulatory and Commercialization Activities

 

		3.1	Development

 

		(a)	Development Plan

 

The initial development plan
is set forth in Schedule 3 (the Initial Development Plan). Licensee will conduct the Development of the Licensed Product
according to the Development Plan. The Development Plan will include, among other things, the indications for which the Licensed
Product is to be Developed and other exploratory indications for which the Product may be developed, critical activities to be
undertaken, certain timelines, go/no go decision points and relevant decision criteria and certain allocations of responsibilities
between the Parties for the various activities to be undertaken under the Development Plan. The Development Plan shall be focused
on efficiently obtaining Regulatory Approval in the Territory, while taking into consideration potential Development, Regulatory
Approval or commercial impacts on the Licensed Product outside of the Territory and the Field. During the Term, the Parties will
review the Development Plan from time to time, not less than twice per calendar year, and will amend such Development Plan on an
ongoing basis as necessary. Any such amendment to the Development Plan will be approved by ArQule; provided, that, under
no circumstances shall Licensee conduct any Development activities as part of a Development Plan that would reasonably be expected
to have a material adverse safety effect on the Development or Commercialization of the Licensed Compound outside of the Territory.
The then-current Development Plan will at all times contain at least that level of detail and cover at least the same matters (to
the extent applicable) as the Initial Development Plan.

 

    	 	17	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(b)	Diligence

 

After the Effective Date, subject
to the Retained Rights, as between the Parties, Licensee shall be solely responsible for all aspects of the Development of the
Licensed Compound and Licensed Products in the Field in the Territory. Without limitation of Clause 3.1(c) (Development Costs),
Licensee shall use Commercially Reasonable Efforts to Develop, and obtain and maintain Regulatory Approvals for, Licensed Products
for use in the Field in the Territory. Licensee shall be solely responsible for all clinical development activities in the Territory
in accordance with the Development Plan. Licensee shall have the right to engage contract research organizations and Affiliates
to handle certain clinical development activities, subject to the execution by each such contract research organization and Affiliate
of an agreement containing provisions with respect to confidentiality, limitations on use and assignment of Know-How that are consistent
with, and no less stringent in scope than, this Agreement.

 

As a part of its diligence obligations
under this Agreement, Licensee agrees to use Commercially Reasonable Efforts to (i) file a CTA for a Licensed Product with the
CFDA prior to December 31, 2018, and (ii) initiate a clinical trial with a Licensed Product by June 30, 2019.

 

		(c)	Development Costs

 

Licensee shall be solely responsible
for all costs and expenses in connection with the Development of, and obtaining and maintaining Regulatory Approvals for, the Licensed
Products in the Field in the Territory.

 

		(d)	Development Records

 

Licensee shall, and shall cause
its Affiliates and its and their Sublicensees to, maintain, in good scientific manner, complete and accurate books and records
pertaining to Development of Licensed Products hereunder, in sufficient detail to verify compliance with its obligations under
this Agreement. Such books and records shall (i) be appropriate for patent and regulatory purposes, (ii) be in compliance with
Applicable Law, (iii) properly reflect all work done and results achieved in the performance of its Development activities hereunder,
(iv) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement
and (v) be retained by Licensee for at least *** years after the expiration or termination of this Agreement in its entirety or
for such longer period as may be required by Applicable Law. ArQule shall have the right, during normal business hours and upon
reasonable notice, to inspect and copy all such books and records maintained pursuant to this Clause 3.1(d) (Development Records);
provided that ArQule shall maintain such records and information disclosed therein in confidence in accordance with Clause
7 (CONFIDENTIALITY AND NON-DISCLOSURE).

 

		(e)	Development Reports

 

		(i)	Licensee shall, as promptly as possible, provide ArQule with copies of all data, as well as all
other information requested by ArQule, generated by Licensee in the conduct of any clinical trials involving the Licensed Compound
and Licensed Products (including all Licensee Development Data).

 

		(ii)	Without limiting Clause 3.1(d) (Development Records) and Clause 3.1(e)(i), at least *** days prior
to each meeting of the JDC and in any event not less than twice per year, during which Licensee is conducting Development activities
hereunder, Licensee shall provide the JDC with a detailed written report of such Development activities it has performed, or caused
to be performed, since the preceding report, its Development activities in process and the future activities it expects to initiate
during the following ***-month period. Each such report shall contain sufficient detail to enable the JDC to assess Licensee's
compliance with its obligations set forth in Clause 3.1(a) (Development Plan), including:

 

		(A)	Licensee's, or its Affiliates' or its or their Sublicensees' activities with respect to achieving
Regulatory Approvals of Licensed Products in the Territory;

 

    	 	18	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(B)	clinical study results and results of other Development activities not otherwise provided under
subsection (i); and

 

		(C)	the Drug Approval Applications that Licensee or any of its Affiliates reasonably expect to make,
seek or attempt to obtain in the Territory.

 

		3.2	Regulatory Activities

 

		(a)	Regulatory Approvals

 

Subject to the Retained Rights,
except as otherwise set forth in this Clause 3.2 (Regulatory Activities), Licensee shall have the sole right and at its sole cost
and expense to prepare, obtain and maintain all Drug Approval Applications (including the setting of the overall regulatory strategy
therefor), other Regulatory Approvals and other submissions (including INDs and CTAs) and to conduct communications with the Regulatory
Authorities, for Licensed Products in the Field in the Territory in its name.

 

		(b)	Regulatory Cooperation

 

		(i)	Licensee shall timely notify ArQule of all material submissions, filings with any Regulatory Authority
and all material notices or communications from any Regulatory Authority that are related to any Licensed Product in the Territory.
Moreover, with respect to regulatory filings in the Territory, Licensee will provide ArQule with drafts of such filings in English
not less than *** days prior to submission so that ArQule may review and comment on them; provided, that any failure by
ArQule to provide comments within the review period shall be deemed an acceptance of the draft and shall not delay Licensee’s
filing date. Licensee shall consider all comments of ArQule in good faith, taking into account the best interests of the Development
and/or Commercialization of the Licensed Product.

 

		(ii)	ArQule shall provide or make available to Licensee copies of material regulatory filings made by
or on behalf of ArQule outside the Territory so that Licensee may, to the extent permitted under Applicable Law, reference them.

 

		(c)	Recalls, Suspensions or Withdrawals

 

Licensee shall notify ArQule
promptly following its determination that any event, incident or circumstance has occurred that would reasonably be expected to
result in the need for a recall, market suspension or market withdrawal of a Licensed Product in the Field in the Territory and
shall include in such notice the reasoning behind such determination and any supporting facts. As between the Parties, Licensee
shall have the right to make the final determination whether to voluntarily implement any such recall, market suspension or market
withdrawal in the Field in the Territory; provided that prior to any implementation of such a recall, market suspension
or market withdrawal, Licensee shall consult with ArQule and shall consider ArQule's comments in good faith. If a recall, market
suspension or market withdrawal is mandated by a Regulatory Authority in the Territory, as between the Parties, Licensee shall
initiate such a recall, market suspension or market withdrawal in compliance with Applicable Law. For all recalls, market suspensions
or market withdrawals undertaken pursuant to this Clause 3.2(c) (Recalls, Suspensions or Withdrawals), as between the Parties,
Licensee shall be solely responsible for the execution thereof. Subject to Clause 9 (INDEMNITY; INSURANCE), Licensee shall be responsible
for all costs and expenses of any such recall, market suspension or market withdrawal.

 

    	 	19	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(d)	Pharmacovigilance Agreement; Global Safety Database

 

The Parties shall enter into
a pharmacovigilance agreement promptly following the Effective Date providing for the terms pursuant to which (i) ArQule (and/or
any current or future license of ArQule of the Licensed Compound and/or any Licensed Products) shall establish, hold and maintain
(at ArQule's sole cost and expense) the global safety database for Licensed Products, (ii) Licensee shall timely provide ArQule
with information in the possession and Control of Licensee or its Affiliates and its or their (sub)licensees as necessary for ArQule
(and/or any current or future license of ArQule of the Licensed Compound and/or any Licensed Products) to comply with its pharmacovigilance
responsibilities outside the Territory, including, as applicable, any adverse drug experiences (including those events or experiences
that are required to be reported to the FDA under 21 C.F.R. sections 312.32 or 314.80 or to foreign Regulatory Authorities under
corresponding Applicable Law outside the United States), from pre-clinical or clinical laboratory, animal toxicology and pharmacology
studies, clinical studies and commercial experiences with a Licensed Product, in each case, in English, in the form reasonably
requested by ArQule and at Licensee’s sole cost and expense, and (iii) ArQule (and/or any current or future license of ArQule
of the Licensed Compound and/or any Licensed Products) shall provide Licensee with access to data in such global safety database
as necessary for Licensee to comply with its pharmacovigilance responsibilities in the Territory, including, as applicable, any
adverse drug experiences (including those events or experiences that are required to be reported to the FDA under 21 C.F.R. sections
312.32 or 314.80 or to foreign Regulatory Authorities under corresponding Applicable Law outside the United States), from pre-clinical
or clinical laboratory, animal toxicology and pharmacology studies, clinical studies and commercial experiences with a Licensed
Product.

 

		(e)	Regulatory Inspections

 

If any Regulatory Authority (i)
contacts Licensee or its Affiliates or its or their (sub)licensees with respect to the alleged improper Development, Manufacture
or Commercialization of any Licensed Product, or (ii) conducts, or gives notice of its intent to conduct, an inspection at Licensee’s
or its Affiliate’s or its or their (sub)licensees’ facilities used in the Development or Manufacturing of Licensed
Products, then Licensee will promptly notify ArQule of such contact, inspection or notice.

 

If any Regulatory Authority takes,
or gives notice of its intent to take, any regulatory action with respect to any activity of such Party or its Affiliates or its
or their (sub)licensees that could reasonably be expected to adversely affect any Development, Manufacture or Commercialization
activities with respect to the Licensed Product in such other Party’s Territory, then such Party will promptly notify the
other Party of such contact, inspection or notice.

 

		3.3	Commercialization

 

		(a)	Commercialization Plan

 

Licensee will prepare and provide
to the JDC a Commercialization Plan for each Licensed Product in the Field in the Territory at least *** days in advance of the
last JDC meeting occurring prior to Licensee’s expected filing of any Drug Approval Application of such Licensed Product
in the Territory. Licensee shall be solely responsible and pay for all Commercialization activities in the Field in the Territory
in accordance with the Commercialization Plan.

 

(b)       Diligence

 

As between the Parties, Licensee
shall be solely responsible for Commercialization of the Licensed Products in the Field throughout the Territory at Licensee's
sole cost and expense. Licensee shall use Commercially Reasonable Efforts to Commercialize the Licensed Products throughout the
Territory.

 

    	 	20	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(c)	Commercialization Costs; Booking of Sales; Distribution

 

Licensee shall invoice and book
sales, establish all terms of sale (including pricing and discounts) and warehouse and distribute the Licensed Products in the
Field in the Territory and perform or cause to be performed all related Commercialization services. Subject to Clause 3.2(c)
(Recalls, Suspensions or Withdrawals), Licensee shall handle all returns, recalls or withdrawals, order processing, invoicing,
collection, distribution and inventory management with respect to the Licensed Products in the Territory.

 

		(d)	Commercialization Records

 

Without limitation of Clause
5.10 (Audit), Licensee shall maintain complete and accurate books and records pertaining to Commercialization of Licensed Products
hereunder, in sufficient detail to verify compliance with its obligations under this Agreement and which shall be in compliance
with Applicable Law and properly reflect all work done and results achieved in the performance of its Commercialization activities.
Such records shall be retained by Licensee for at least *** years after the expiration or termination of this Agreement in its
entirety or for such longer period as may be required by Applicable Law. ArQule shall have the right, during normal business hours
and upon reasonable notice, to inspect and copy all such books and records maintained pursuant to this Clause 3.3(d) (Commercialization
Records); provided that ArQule shall maintain such records and information disclosed therein in confidence in accordance
with Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE).

 

		(e)	Commercialization Reports

 

Without limiting Clause 3.3(e)
(Commercialization Reports), at least thirty (30) days prior to each JDC meeting and in any event not less than once per Calendar
Year, following the preparation of the initial Commercialization Plan, Licensee shall provide ArQule with detailed written
reports of all Commercialization activities it has performed, or caused to be performed, since the preceding report and the future
activities it expects to initiate during the following ***-month period, broken down by Calendar Quarter. Each such report shall
contain sufficient detail to enable ArQule to assess Licensee's compliance with its obligations set forth in Clauses 3.3(a) (Commercialization
Plan) and 3.3(c) (Commercialization Costs; Booking of Sales; Distribution), including, in each case, Net Sales for such Licensed
Product in the Territory.

 

		3.4	Statements and Compliance with Applicable Law

 

Licensee shall and shall cause
its Affiliates to, comply with all Applicable Law with respect to the Exploitation of Licensed Products. Licensee shall avoid and
shall cause its Affiliates and its and their Sublicensees, employees, representatives, agents, and distributors to avoid, taking
or failing to take, any actions that Licensee knows or reasonably should know would jeopardize the goodwill or reputation of ArQule
or the Licensed Products or any Trademark associated therewith. Without limitation to the foregoing, Licensee shall in all material
respects conform to its practices and procedures relating to the Commercialization of the Licensed Products and educating the medical
community in the Territory with respect to the Licensed Products to any applicable industry association regulations, policies and
guidelines, as the same may be amended from time to time, and Applicable Law.

 

		3.5	Supply of Licensed Products

 

		(a)	Responsibility

 

As between the
Parties, Licensee will have the sole responsibility, at its sole cost and expense, for Manufacturing (or having Manufactured) and
supplying the Licensed Compound and any Licensed Products in the Territory for its Development and Commercialization activities
in the Field in the Territory. Licensee shall use Commercially Reasonable Efforts to Manufacture (or have Manufactured) the Licensed
Compound and any Licensed Products in quantities that are sufficient for Licensee’s Development and Commercialization activities
in the Field in the Territory.

 

    	 	21	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(b)	Technology and other Know How transfer assistance
from ArQule

 

		(i)	ArQule Know-How and Licensed Compound

 

As soon as practicable and in no
event later than *** days after the Effective Date, ArQule will provide or make available to Licensee the ArQule Know-How listed
in Schedule 4.

 

		(ii)	Transfer of Materials

 

ArQule shall make available for
a one-time transfer to Licensee in a mutually agreed manner, the quantities of Licensed Compound and available working standards
for the Licensed Compound, as set forth on Schedule 2. Such inventory shall only be used in pre-clinical and clinical work in accordance
with the license grant in Clause 2.1 (Grants to Licensee) and shall not be used for commercial purposes. For avoidance of doubt,
any amounts of Licensed Compound transferred by ArQule to Licensee under this Clause 3.5 (Supply of Licensed Products) shall not
be used by Licensee to Manufacture Licensed Product other than for use in pre-clinical and clinical work. ArQule shall have no
further obligation to make any further Licensed Compound inventory available to Licensee; provided, that ArQule will provide
Licensee the ability to opt-in to any manufacturing run occurring in 2018, with Licensee paying its pro rata share of the costs
of such manufacturing run. Licensee acknowledges and agrees that, prior to use of the transferred Licensed Compound for pre-clinical
and clinical work, Licensee shall conduct stability testing and testing to determine whether such Licensed Compound meets the relevant
specifications, at Licensee's own expense. ArQule shall provide to Licensee the current certificate of analysis for the Licensed
Compound that exists as of the Effective Date, but shall not be obligated to re-test any batches of expired Licensed Compound.
For the avoidance of doubt, ArQule makes no representation or warranty that such Licensed Compound meets any of the specifications,
and any use of such Licensed Compound by Licensee shall not be subject to any claim for indemnification by Licensee under Clause
9.2 (Indemnification of Licensee).

 

		(iii)	Shipping

 

Licensee shall be responsible for
the shipping cost from current warehousing location(s) where the Licensed Compound resides, importation paperwork, and any applicable
customs/duties. Licensee shall select and engage the shipper and any customs broker at its own cost and expense. The risk of loss
from any casualty to the Licensed Compound, regardless of the cause, shall be transferred to Licensee upon delivery of the Licensed
Compound to the shipper. In addition, Licensee shall cause the shipper to ensure that the Licensed Compound is stored and shipped
in conditions that do not adversely affect the Licensed Compound's stability and integrity.

 

		(iv)	Transfer Completion Notice

 

ArQule shall issue to Licensee,
in writing, a Transfer Completion Notice upon completion of ArQule's obligations under Clause 3.5(b)(i) (ArQule Know-How and Licensed
Compound) and Clause 3.5(b)(ii) (Transfer of Materials) above (the Transfer Completion Notice). Licensee shall have ***
Business Days following receipt of the Transfer Completion Notice to send confirmation in writing to ArQule that ArQule has effectively
completed its obligations under Clause 3.5(b)(i) (ArQule Know-How and Licensed Compound) and Clause 3.5(b)(ii) (Transfer of Materials)
(the Transfer Confirmation Notice); provided, that, if Licensee fails to send the Transfer Confirmation Notice within
such ***-Business Day period, ArQule shall be deemed to have effectively completed its obligations under Clause 3.5(b)(i) (ArQule
Know-How and Licensed Compound) and Clause 3.5(b)(ii) (Transfer of Materials).

 

    	 	22	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(v)	Technical Support

 

For a period not to exceed ***
months from the Effective Date, ArQule will provide Licensee with up to *** hours of technical support at no additional cost upon
Licensee's request in order to ensure an orderly transition of the ArQule Know-How to Licensee (or its designee) and to Assist
Licensee (or its designee) in the start-up of its Manufacture of Licensed Compound and Licensed Product; provided, that
Licensee provides ArQule with no less than *** days' notice of its intent to use such technical support. Such technical support
may, at Licensee's request, include, without limitation, the following activities:

 

		(A)	a list of questions, in writing, that Licensee may reasonably raise after having reviewed the ArQule
Know-How disclosed or made available by ArQule listed on Schedule 4; and

 

		(B)	a list of questions, in writing, that Licensee may reasonably raise as part of its Manufacture
of Licensed Compound or Licensed Product.

 

ArQule will also make reasonable
efforts to provide responses to questions Licensee may reasonably raise as Licensee initiates process development, and completes
and releases registration batches, to the extent that internal resources are available to answer any such questions. For clarity,
however, nothing herein requires ArQule to provide assistance beyond the ***-month period as specified in this Clause 3.5 (b)(v)
(Technical Support).

 

		(vi)	Complete Transfer

 

The Parties acknowledge that ArQule
shall have completed its contractual obligations under this Agreement with respect to technical support upon the completion of
the activities described in this Clause 3.5 (Supply of Licensed Products).

 

		(vii)	Transfer of ArQule Know-How

 

ArQule shall provide ArQule Know-How
as described in Schedule 4 and the Regulatory Documentation in electronic format only. ArQule shall be responsible for all costs
and expenses associated with transfer of ArQule Know-How and Regulatory Documentation. For the avoidance of doubt, unless reasonably
necessary to obtain Regulatory Approval, ArQule shall have no obligation to provide the source documentation or any additional
data, in any form, other than that provided within the ArQule Know-How as listed in Schedule 4.

 

    	 	23	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		3.6	Subcontracting

 

Subject to Clause 2.3 (Sublicenses),
Licensee may subcontract with an Affiliate or a Third Party to perform any or all of its obligations hereunder (including by appointing
one (1) or more distributors); provided that (a) no such permitted subcontracting shall relieve Licensee of any obligation
hereunder (except to the extent satisfactorily performed by such subcontractor) or any liability and Licensee shall be and remain
fully responsible and liable therefor and (b) the agreement pursuant to which Licensee engages any Third Party subcontractor
must (i) be consistent in all material respects with this Agreement, (ii) contain terms obligating such subcontractor
to comply with the confidentiality, restriction on use, intellectual property and all other relevant provisions of this Agreement,
(iii) contain terms that provide that Licensee will Control all intellectual property developed by the subcontractor in the course
of performing any such work and own all such intellectual property that is specifically related to, or otherwise necessary for
Development, Manufacture or Commercialization of the Licensed Compound or any Licensed Product such that Licensee will be able
to comply with its obligations to assign or license Inventions to ArQule as provided under this Agreement and (iv) contain
terms obligating such subcontractor to permit ArQule rights of inspection, access and audit substantially similar to those provided
to ArQule in this Agreement. Licensee shall ensure that each subcontractor accepts and complies with all of the applicable terms
and conditions of this Agreement as if such permitted subcontractor were a Party to this Agreement. Licensee hereby waives any
requirement that ArQule exhaust any right, power or remedy, or proceed against any Third Party subcontractor for any obligation
or performance under this Agreement prior to proceeding directly against Licensee.

 

3.7       Companion
Diagnostics

 

ArQule agrees to use Commercially
Reasonable Efforts to either (a) negotiate with its Third Party supplier of the break apart FISH assays that ArQule is currently
using in the European Union for the testing of patients in its ongoing clinical trial in iCCA (the ArQule Fish Assay) to
supply Licensee directly with a version of such ArQule Fish Assay pursuant to a separate supply agreement between Licensee and
such Third Party supplier so that Licensee or its designee(s) can seek Regulatory Approval of the test in the Territory, or (b)
amend its existing agreement with such Third Party supplier to include the Territory as an additional market such that the Third
Party supplier would obtain Regulatory Approval to sell a version of the ArQule Fish Assay in the Territory, in either case (i)
at Licensee’s sole cost and expense and (ii) for use by Licensee in its clinical trial in intrahepatic cholangiocarcinoma
(iCCA) in the Territory. Licensee shall be further responsible for conducting, and paying all costs and expenses for, the Development
of any diagnostic test used to identify patients in any clinical trial conducted under the Development Plan and for the Regulatory
Approval and Commercialization of any such test for use with a Licensed Product in the Field in the Licensed Territory.

 

		4.	DEVELOPMent Committee

 

		4.1	Joint Development Committee

 

Within *** days after the Effective
Date, the Parties shall establish a joint development committee (the Joint Development Committee or JDC), which shall
consist of *** representatives from each of the Parties, each with the requisite authority to enable such person to make decisions
on behalf of the Parties with respect to the issues falling within the jurisdiction of the JDC. From time to time, each Party may
substitute one (1) or more of its representatives to the JDC on written notice to the other Party. Licensee shall select from its
representatives the chairperson for the JDC, which chairperson may be changed from time to time, on written notice to ArQule. The
JDC shall:

 

		(a)	serve as a forum for discussing and supervising Development of the Licensed Compound and Licensed
Products in the Field in the Territory, including by reviewing Development Plans and overseeing the conduct of the Development
activities as provided in Clause 3.1 (Development), and reviewing Development reports as provided in Clause 3.1(e) (Development
Reports);

 

		(b)	serve as a forum for discussing and supervising the Commercialization of Licensed Products in the
Field in the Territory as provided in Clause 3.3 (Commercialization), including by establishing the Commercialization strategy
for the Territory, reviewing the Commercialization Plans and overseeing the conduct of the Commercialization activities;

 

		(c)	co-ordinate the Parties' activities under this Agreement; and

 

    	 	24	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(d)	perform such other functions as are set forth herein or as the Parties may mutually agree in writing,
except where in conflict with any provision of this Agreement.

 

		4.2	General Provisions Applicable to the JDC

 

		(a)	Meetings and Minutes

 

The JDC shall meet semi-annually
or as otherwise agreed to by the Parties, with the location of such meetings alternating between locations designated by Licensee
and locations designated by ArQule. Either Party shall have the right to call meetings on not less than *** Business Days' notice
unless exigent circumstances require shorter notice. Each Party shall make all proposals for agenda items at least *** Business
Days in advance of the applicable meeting and shall provide all appropriate information with respect to such proposed items at
least *** Business Days in advance of the applicable meeting; provided that under exigent circumstances requiring input
by the JDC, a Party may provide its agenda items to the other Party within a shorter period of time in advance of the meeting or
may propose that there not be a specific agenda for a particular meeting, so long as the other Party consents to such later addition
of such agenda items or the absence of a specific agenda for such meeting (which consent shall not be unreasonably withheld, conditioned
or delayed). The chairperson of the JDC (or his or her designee) shall prepare and circulate the meeting agenda at least *** Business
Days in advance of the meeting, and shall prepare and circulate for review and approval of the Parties minutes of each meeting
as promptly as possible after the meeting. The Parties shall agree on the minutes of each meeting promptly, but in no event later
than the next meeting of the JDC.

 

		(b)	Procedural Rules

 

The JDC shall have the right
to adopt such standing rules as shall be necessary for its work, to the extent that such rules are not inconsistent with this Agreement.
A quorum of the JDC shall exist whenever there is present at a meeting at least one (1) representative appointed by each Party.
Representatives of the Parties on the JDC may attend a meeting either in person or by telephone, video conference or similar means
in which each participant can hear what is said by, and be heard by, the other participants. Representation by proxy shall be allowed.
The JDC shall take action by consensus of the representatives present at a meeting at which a quorum exists, with each Party having
a single vote irrespective of the number of representatives of such Party in attendance or by a written resolution signed by at
least one (1) representative appointed by each Party. Alliance Managers or other employees or consultants of a Party who are not
representatives of the Parties on the JDC may attend meetings of the JDC; provided, however, that such attendees (i) shall
not vote or otherwise participate in the decision-making process of the JDC and (ii) are bound by obligations of confidentiality
and non-disclosure at least as protective of the other Party as those set forth in Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE).

 

		(c)	Decision-Making

 

Except for matters outside the
jurisdiction and authority of the JDC, if the JDC cannot, or does not, reach consensus on an issue, then, (i) to the extent that
the issue involves a Unanimous Decision, such issue must be mutually agreed by the Senior Officers and shall not be submitted to
arbitration and otherwise (ii) subject to subsection (i), such issue shall be resolved pursuant to Clause 11.5 (Governing Law and
Dispute Resolution).

 

    	 	25	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(d)	Limitations on Authority

 

Without limitation to the foregoing,
the Parties hereby agree that matters explicitly reserved to the consent, approval or other decision-making authority of one or
both Parties, as expressly provided in this Agreement between the Parties, are outside the jurisdiction and authority of the JDC,
including (i) amendment, modification or waiver of compliance with this Agreement (which may only be amended or modified as provided
in Clause 11.7 (Entire Agreement; Amendments) or compliance with which may only be waived as provided in Clause 11.10
(Waiver and Non-Exclusion of Remedies) and (ii) such other matters as are reserved to the consent, approval, agreement or other
decision-making authority of either or both Parties in this Agreement that are not required by this Agreement to be considered
by the JDC prior to the exercise of such consent, approval or other decision-making authority.

 

		(e)	Alliance Managers

 

Each Party shall appoint a person(s)
who shall oversee contact between the Parties for all matters between meetings of the JDC, which person(s) may be replaced at any
time by notice in writing to the other Party. The Alliance Managers shall work together to manage and facilitate the communication
between the Parties under this Agreement, including the resolution (in accordance with the terms of this Agreement) of issues between
the Parties that arise in connection with this Agreement. The Alliance Managers shall not have final decision-making authority
with respect to any matter under this Agreement.

 

		(f)	Appointment Not an Obligation. 

 

The appointment
of any members of a committee and Alliance Managers is a right of each Party and not an obligation and shall not be a “deliverable”
as defined in EITF Issue No. 00-21. Each Party shall be free to determine not to appoint members to any committee and not to appoint
an Alliance Manager. If a Party (the “non-Appointing Party”) does not appoint members of any Committee or an
Alliance Manager, it shall not be a breach of this Agreement, nor shall any consideration be required to be returned, and the other
Party (the “Appointing Party”) shall have the votes and the decision-making power of the non-Appointing Party
unless and until such members are appointed by the non-Appointing Party.

 

		(g)	Discontinuation; Disbandment; Annual Reports

 

Subject to Clause 4.2(f) (Appointment
Not an Obligation), once established, the JDC shall continue to exist until the first to occur of:

 

		(i)	the Parties mutually agreeing to disband the JDC; and

 

		(ii)	ArQule providing to Licensee written notice of its intention to disband the JDC. Upon the occurrence
of either of the foregoing, (A) the JDC shall disband, have no further responsibilities or authority under this Agreement and will
be considered dissolved by the Parties and (B) any requirement of a Party to provide Information or other materials to the JDC
shall be deemed a requirement to provide such Information or other materials to the other Party’s Alliance Manager and Licensee
shall have the right to decide all matters that are subject to the review or approval by the JDC hereunder, with any Disputes to
be resolved pursuant to Clause 11.5 (Governing Law and Dispute Resolution).

 

		5.	Payments and Records

 

		5.1	Upfront Payment

 

In partial consideration of the
rights granted by ArQule to Licensee hereunder, no later than thirty (30) days following the Effective Date, Licensee shall pay
ArQule a non-refundable and non-creditable upfront amount equal to three million Dollars ($3,000,000).

 

    	 	26	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		5.2	Regulatory Milestones

 

As additional consideration for
the rights granted to Licensee pursuant to Clause 2.1 (Grants to Licensee), Licensee will notify ArQule within *** days of the
achievement of each of the following events (each, a Regulatory Milestone Event). ArQule shall promptly invoice Licensee
for the corresponding amount below, and Licensee shall pay to ArQule the following one-time milestone payments within *** days
of receipt of such invoice.

 

	Regulatory Milestone Event	 	Milestone 
 Payment	 
	Submission of Clinical Trial Application (CTA) to CFDA for Licensed Product or ***, whichever is earlier.	 	$	***	
	Regulatory Approval of a Licensed Product in the first indication	 	$	***	 
	Regulatory Approval of a Licensed Product in the second indication	 	$	***	 
	Regulatory Approval of a Licensed Product in the third indication	 	$	***	 

 

In the event that, notwithstanding
the fact that Licensee has not given such a notice, ArQule believes any such milestone event has occurred, it shall so notify Licensee
in writing and shall provide to Licensee data, documentation or other information that supports its belief. Any dispute under this
Clause 5.2 (Regulatory Milestone) that relates to whether or not a milestone event has occurred shall be referred to the JDC to
be resolved in accordance with Clause 4 (DEVELOPMENT COMMITTEE) and shall be subject to resolution in accordance with Clause 11.5
(Governing Law and Dispute Resolution). Once Licensee has made any particular milestone payment under this Clause 5.2 (Regulatory
Milestones), Licensee will not be obligated to make any payment with respect to the re-occurrence of the same milestone event.
If any two of the milestone events above occur in the same Calendar Year, both applicable milestone payments will be due and payable
to ArQule. The above milestone payments shall be non-creditable and non-refundable. If at the time any given milestone payment
set forth in Clause 5.2 (Regulatory Milestones) is due and one (1) or more preceding milestone payments for antecedent milestone
events have not been paid, then such unpaid antecedent milestone payments shall be paid at such time as well.

 

		5.3	Commercial Milestones

 

As additional consideration for
the rights granted to Licensee pursuant to Clause 2.1 (Grants to Licensee), Licensee will notify ArQule of the achievement of each
of the following events (each, a Commercial Milestone Event) within *** days of the end of the Calendar Quarter in which
such event occurs. ArQule shall promptly invoice Licensee for the corresponding amount below, and Licensee shall pay to ArQule
the following one-time milestone payments within *** days of receipt of such invoice.

 

	Commercial Milestone Event	 	Milestone 
 Payment	 
	First Calendar Year in which the aggregate annual Net Sales of all Licensed Products in the Territory exceed $***	 	$	***	
	First Calendar Year in which the aggregate annual Net Sales of all Licensed Products in the Territory exceed $***	 	$	***	 
	First Calendar Year in which the aggregate annual Net Sales of all Licensed Products in the Territory exceed $***	 	$	***	 
	First Calendar Year in which the aggregate annual Net Sales of all Licensed Products in the Territory exceed $***	 	$	***	 

 

    	 	27	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

In the event that, notwithstanding
the fact that Licensee has not given such a notice, ArQule believes any such milestone event has occurred, it shall so notify Licensee
in writing and shall provide to Licensee data, documentation or other information that supports its belief. Any dispute under this
Clause 5.3 (Commercial Milestones) that relates to whether or not a milestone event has occurred shall be referred to the JDC to
be resolved in accordance with Clause 4 (DEVELOPMENT COMMITTEE) and shall be subject to resolution in accordance with Clause 11.5
(Governing Law and Dispute Resolution). Once Licensee has made any particular milestone payment under this Clause 5.3 (Commercial
Milestones), Licensee will not be obligated to make any payment with respect to the re-occurrence of the same Milestone Event.
If any two of the Milestone Events above occur in the same Calendar Year, both applicable milestone payments will be due and payable
to ArQule. The above milestone payments shall be non-creditable and non-refundable. If at the time any given milestone payment
set forth in Clause 5.3 (Commercial Milestones) is due and one (1) or more preceding milestone payments for antecedent milestone
events have not been paid, then such unpaid antecedent milestone payments shall be paid at such time as well.

 

		5.4	Royalties

 

		(a)	Royalty Rate

 

As further consideration for
the rights granted to Licensee hereunder, commencing upon the First Commercial Sale of a Licensed Product in the Territory and
continuing for the remainder of the applicable Royalty Term, Licensee shall pay to ArQule a royalty on Net Sales of each Licensed
Product in the Territory during each Calendar Year at a royalty rate of *** percent (***%).

 

		(b)	Blended Royalty

 

Licensee acknowledges that (i)
the ArQule Know-How and the Information included in the ArQule Regulatory Documentation licensed to Licensee are proprietary and
valuable and that without the Licensee Know-How and such Information, Licensee would not be able to obtain and maintain Regulatory
Approvals with respect to the Licensed Products, (ii) such Regulatory Approvals will allow Licensee to obtain and maintain regulatory
exclusivity with respect to the Licensed Products in the Field in the Territory, (iii) access to the Licensee Know-How and the
rights with respect to the ArQule Regulatory Documentation have provided Licensee with a competitive advantage in the marketplace
beyond the exclusivity afforded by the ArQule Patents and the regulatory exclusivity and (iv) upfront payment and royalties set
forth in Clauses 5.1 (Upfront Payment) and 5.3 (Commercial Milestones), respectively, are, in part, intended to compensate ArQule
for such exclusivity and such competitive advantage. The Parties agree that the royalty rate set forth in Clause 5.4(a) (Royalty
Rate) reflects an efficient and reasonable blended allocation of the value provided by ArQule to Licensee.

 

		(c)	Royalty Term

 

Licensee shall have no obligation
to pay any royalty with respect to Net Sales of any Licensed Product in any country after the Royalty Term for such Licensed Product
in such country has expired. Upon the expiration of the Royalty Term with respect to a Licensed Product in any country, the license
grants to Licensee in Clause 2.1 (Grants to Licensee), as applicable, with respect to such Licensed Product shall convert to non-exclusive
and shall become fully paid-up with respect to such country.

 

    	 	28	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(d)	Reductions

 

In the event that in any country
in the Territory during the Royalty Term for a Licensed Product, unit sales of all Generic Products in such country in a Calendar
Quarter is:

 

		(i)	equal to or greater than *** percent (***%) but less than *** percent (***%) of the sum of unit
sales of such Licensed Product and all such Generic Products in such country, then, commencing upon that particular Calendar Quarter
and for the remainder of the Royalty Term for such Licensed Product in such country thereafter, the royalty rate for such indication(s)
set forth in Clause 5.4 (Royalties) with respect to such country, each shall be reduced by *** percent (***%); or

 

		(ii)	equal to or greater than *** percent (***%) of the sum of unit sales of such Licensed Product and
all such Generic Products in such country, then, commencing upon that particular Calendar Quarter and for the remainder of the
Royalty Term for such Licensed Product in such country thereafter, the royalty rate for such indication(s) set forth in Clause
5.4(a) (Royalty Rate) with respect to such country, each shall be reduced by *** percent (***%).

 

Unit sales shall be measured
by IMS Health Data (or, in the absence of such data, an appropriate end user-level database). Notwithstanding the foregoing, Licensee’s
obligation to pay royalties at the full royalty rates shall be reinstated on the first day of the Calendar Quarter immediately
following the Calendar Quarter in which sales of such Generic Products account for *** percent (***%) or less of the aggregate
unit sales of Licensed Products and Generic Products in such country.

 

If Licensee or its Affiliates
are required, or determines in good faith that it is reasonably necessary, to obtain a license to any Patents of such Third Parties
to Manufacture or Commercialize the Licensed Compound portion of any Licensed Product and makes any royalty payments to such third
parties under any such in-license agreement, Licensee may deduct *** percent (***%) of such royalty payments from royalties thereafter
payable to ArQule.

 

Notwithstanding
anything to the contrary in this Section 5.4, if any Licensed Product is sold by Licensee or any of its Affiliates or Sublicensees
in a country and is not covered by a Valid Claim of the ArQule Patents in such country, the royalty rate in such country shall
be reduced by *** percent (***%) of the rate set forth in Clause 5.4(a) (Royalty Rate), continuing until the last day of the applicable
Royalty Term with respect to such Licensed Product.

 

Notwithstanding anything to the
contrary in this Clause 5.4 (Royalties), in no event shall any royalty payment payable to ArQule for any Licensed Product in a
given calendar quarter be reduced as a result of the payment reductions set forth in this Clause 5.4 (Royalties) to less than ***
percent (***%) of the amount otherwise payable to ArQule.

 

		5.5	Royalty Payments and Reports

 

Licensee shall calculate all
amounts payable to ArQule pursuant to Clause 5.4 (Royalties) at the end of each Calendar Quarter, which amounts shall be converted
to Dollars, in accordance with Clause 5.6 (Mode of Payment; Offsets). Licensee shall pay to ArQule the royalty amounts due with
respect to a given Calendar Quarter within *** days after the end of such Calendar Quarter. Each payment of royalties due to ArQule
shall be accompanied by a statement specifying, on a Licensed Product-by-Licensed Product basis, the amount of Invoiced Sales,
Net Sales and deductions taken to arrive at Net Sales attributable to each Licensed Product in the Territory during the applicable
Calendar Quarter (including such amounts expressed in local currency and as converted to Dollars) and a calculation of the amount
of royalty payment due on such Net Sales for such Calendar Quarter. Without limiting the generality of the foregoing, Licensee
shall require its Affiliates and Sublicensees to account for their Net Sales and to provide such reports with respect thereto,
as if such sales were made by Licensee.

 

    	 	29	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		5.6	Mode of Payment; Offsets

 

All payments to ArQule under
this Agreement shall be made by deposit of Dollars in the requisite amount to such bank account as ArQule may from time to time
designate by notice to Licensee. For the purpose of calculating any sums due under, or otherwise reimbursable pursuant to, this
Agreement (including the calculation of Net Sales expressed in currencies other than Dollars), Licensee shall convert any amount
expressed in a foreign currency into Dollar equivalents using its, its Affiliate's or Sublicensee's, as applicable, standard conversion
methodology consistent with GAAP and reasonably acceptable to ArQule. Licensee shall have no right to offset, set off or deduct
any amounts from or against the amounts due to ArQule hereunder.

 

ArQule may direct that all or
any portion of any payments be paid to any ArQule Affiliate, so long as such instruction does not result in adverse tax consequences
to Licensee.

 

		5.7	Taxes

 

		(a)	General

 

The milestones and royalties
payable by Licensee to ArQule pursuant to this Agreement (each, a Payment) shall be paid free and clear of any and all taxes
(which, for clarity, shall be the responsibility of Licensee), except for any withholding taxes required by Applicable Law. ArQule
shall be solely responsible for paying any and all taxes (other than withholding taxes required by Applicable Law to be deducted
from Payments and remitted by Licensee) levied on account of, or measured in whole or in part by reference to, any Payments it
receives. Licensee shall deduct or withhold from the Payments any taxes that it is required by Applicable Law to deduct or withhold.
Notwithstanding the foregoing, if ArQule is entitled under any applicable tax treaty to a reduction of rate of, or the elimination
of, applicable withholding tax, it may deliver to Licensee or the appropriate governmental authority (with the reasonable assistance
of Licensee to the extent that this is reasonably required and is requested in writing) the prescribed certification, identification
or other reporting requirements necessary to reduce the applicable rate of withholding or to relieve Licensee of its obligation
to withhold such tax and Licensee shall apply the reduced rate of withholding or dispense with withholding, as the case may be;
provided that Licensee has received evidence of ArQule's delivery of all applicable forms (and, if necessary, its receipt
of appropriate governmental authorization) at least fifteen (15) days prior to the time that the Payments are due. If, in
accordance with the foregoing, Licensee withholds any amount, it shall pay to ArQule the balance of the applicable Payment when
due, make timely payment to the proper taxing authority of the withheld amount and send to ArQule proof of such payment within
ten (10) days following such payment. To the extent that amounts are so withheld and paid by Licensee to the proper taxing
authority, such amounts shall be treated for all purposes of this Agreement as having been paid to ArQule.

 

		(b)	Value Added Tax

 

Notwithstanding anything contained
in Clause 5.7(a) (General), this Clause 5.7(b) (Value Added Tax) shall apply with respect to value added tax (VAT). All
Payments are exclusive of VAT. If any VAT is chargeable in respect of any Payments, Licensee shall pay VAT at the applicable rate
in respect of any such Payments following the receipt of a VAT invoice in the appropriate form issued by ArQule in respect of those
Payments, such VAT to be payable on the later of the due date of the payment of the Payments to which such VAT relates and thirty
(30) days after the receipt by Licensee of the applicable invoice relating to that VAT payment. The Parties shall reasonably
cooperate in accordance with Applicable Law to minimize indirect Taxes (such as VAT, sales tax, consumption tax and other similar
Taxes) in connection with this Agreement.

 

    	 	30	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		5.8	Interest on Late Payments

 

If any payment due to either
Party under this Agreement is not paid when due, then, in addition to any other rights and remedies available to the other Party
under this Agreement, such paying Party shall pay interest thereon (before and after any judgment) at an annual rate (but with
interest accruing on a daily basis) of *** basis points above the then-current prime rate quoted by Citibank in New York City,
such interest to run from the date on which payment of such sum became due until payment thereof in full together with such interest.

 

		5.9	Financial Records

 

Licensee shall, and shall cause
its Affiliates and its and their Sublicensees to, keep complete and accurate financial books and records pertaining to the Commercialization
of Licensed Products hereunder, including books and records of Invoiced Sales and Net Sales of Licensed Products, in sufficient
detail to calculate and verify all amounts payable hereunder. Licensee shall, and shall cause its Affiliates and its and their
Sublicensees to, retain such books and records until the later of (a) *** years after the end of the period to which such
books and records pertain, (b) the expiration of the applicable tax statute of limitations (or any extensions thereof) and
(c) for such period as may be required by Applicable Law.

 

		5.10	Audit

 

At the request of ArQule, Licensee
shall and shall cause its Affiliates and its and their Sublicensees to, permit ArQule or an independent auditor designated by ArQule
and reasonably acceptable to Licensee, at reasonable times and upon at least *** days written notice, no more than once in a Calendar
Year during the Term and no more than twice in the *** Calendar Years following termination of this Agreement, to audit the books
and records maintained pursuant to Clause 5.9 (Financial Records) to ensure the accuracy of Net Sales reported and payments
made hereunder (Audit). No period shall be subject to more than one (1) Audit. The independent public accountant shall disclose
to ArQule only (a) the accuracy of Net Sales reported and the basis for royalty and other payments made to ArQule under this Agreement
and (b) the difference, if any, such reported and paid amounts vary from amounts determined as a result of the Audit. Except as
provided below, the cost of this Audit shall be borne by ArQule, unless the Audit reveals, with respect to a period, a variance
of more than *** percent (***%) from the reported amounts for such period, in which case Licensee shall bear the cost of the Audit.
Unless disputed pursuant to Clause 5.11 below (Audit Dispute) below, if such Audit concludes that (i) additional amounts
were owed by Licensee, Licensee shall pay the additional amounts, with interest from the date originally due as provided in Clause 5.8
(Interest on Late Payments) or (ii) excess payments were made by Licensee, ArQule shall reimburse such excess payments, in
either case ((i) or (ii)), within *** days after the date on which such Audit is completed by ArQule.

 

		5.11	Audit Dispute

 

In the event of a dispute with
respect to any Audit under Clause 5.10 (Audit), ArQule and Licensee shall work in good faith to resolve the disagreement.
If the Parties are unable to reach a mutually acceptable resolution of any such dispute within *** days, the dispute shall be submitted
for resolution to a certified public accounting firm jointly selected by each Party's certified public accountants or to such other
Person as the Parties shall mutually agree (the Auditor). The decision of the Auditor shall be final and the costs of such
arbitration as well as the initial Audit shall be borne between the Parties in such manner as the Auditor shall determine. Not
later than *** days after such decision and in accordance with such decision, Licensee shall pay the additional amounts, with interest
from the date originally due as provided in Clause 5.8 (Interest on Late Payments) or ArQule shall reimburse the excess payments,
as applicable.

 

    	 	31	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		6.	Intellectual Property

 

		6.1	Ownership of Intellectual Property

 

		(a)	Ownership of Technology

 

As between the Parties:

 

		(i)	ArQule shall solely own on a worldwide basis all right, title and interest in and to any and all
ArQule Know-How, ArQule Inventions and Compound-Specific Inventions, whether or not patented or patentable, and any and all ArQule
Patents, ArQule Invention Patents and Compound-Specific Invention Patents, and any other intellectual property rights with respect
thereto;

 

		(ii)	Licensee shall solely own on a worldwide basis all right, title and interest in and to any and
all Licensee Know-How and Licensee Inventions, whether or not patented or patentable, and any and all Licensee Patents and Licensee
Invention Patents, and any other intellectual property rights with respect thereto; and

 

		(iii)	each Party shall own on a worldwide basis and retain all right, title and interest in and to any
and all Information, inventions, Patents and other intellectual property rights that are owned or otherwise Controlled (other than
pursuant to the license grants set forth in Clauses 2.1 (Grants to Licensee) and 2.2 (Grants to ArQule)) by such Party or
its Affiliates or its or their (sub)licensees (or Sublicensees) (as applicable) outside of this Agreement.

 

		(b)	Ownership of Joint Patents and Joint Inventions

 

As between the Parties, each
of ArQule and Licensee shall own an equal, undivided interest in any and all:

 

		(i)	Inventions (other than Compound-Specific Inventions) that are conceived, discovered, developed
or otherwise made jointly by or on behalf of ArQule or its Affiliates or its or their (sub)licensees, on the one hand, and Licensee
or its Affiliates or its or their Sublicensees, on the other hand, whether or not patented or patentable (the Joint Inventions);
and

 

		(ii)	Patents that are derived from or filed based on Joint Inventions, referred to herein as the Joint
Patents and, together with the Joint Inventions, the Joint Intellectual Property Rights. Each Party shall promptly disclose
to the other Party in writing and shall cause its Affiliates and its and their (sub)licensees (or Sublicensees) to so disclose,
the development, making, conception or reduction to practice of any Joint Inventions. Subject to the licenses granted under Clauses
2.1 (Grants to Licensee) and 2.2 (Grants to ArQule), each Party shall have the right to Exploit the Joint Intellectual Property
Rights without a duty of seeking consent or accounting to the other Party.

 

    	 	32	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(c)	United States Law

 

The determination of whether
Information and other Inventions are conceived, discovered, Developed or otherwise made by a Party for the purpose of allocating
proprietary rights (including Patent, copyright or other intellectual property rights) therein, shall, for purposes of this Agreement,
be made in accordance with Applicable Law in the United States as such law exists as of the Effective Date irrespective of where
or when such conception, discovery, Development or making occurs. Each Party shall, and does hereby, assign, and shall cause its
Affiliates and its and their (sub)licensees (or Sublicensees) to so assign, to the other Party, without additional compensation,
such right, title and interest in and to any Information, and other Inventions as well as any intellectual property rights with
respect thereto, as is necessary to fully effect, as applicable, (i) the sole ownership provided for in Clause 6.1(a) (Ownership
of Intellectual Property) and (ii) the joint ownership provided for in Clause 6.1(b) (Maintenance and Prosecution Patents).

 

		(d)	Assignment Obligation

 

Each Party shall cause all Persons
who perform Development activities, Manufacturing activities or regulatory activities for such Party under this Agreement or who
conceive, discover, Develop or otherwise make any Information or other inventions by or on behalf of either Party or its Affiliates
or its or their (sub)licensees (or Sublicensees) under or in connection with this Agreement to be under an obligation to assign
their rights in any Information, and inventions resulting therefrom to such Party, except where Applicable Law requires otherwise
and except in the case of governmental, not-for-profit and public institutions that have standard policies against such an assignment
(in which case, a suitable license or right to obtain such a license, shall be obtained).

 

		(e)	Ownership of Product Trademarks

 

Licensee shall have the right
to market the Licensed Products in the Field in the Territory under the Trademarks of its choice; provided, that Licensee may not
include in any such Trademarks any Corporate Names or any reference to any products of ArQule or any of its Affiliates or licensees
without the prior written consent of ArQule (any such Trademarks, the “Product Trademarks”), and all goodwill
associated therewith will inure to the benefit of Licensee. Upon termination of this Agreement, upon the request of ArQule, Licensee
shall assign, transfer and convey all of its rights in the Product Trademarks and domain names containing such Product Trademarks,
to ArQule or its designated assignee; provided, however, that this provision shall not apply to any trademarks or domain
names including the name of Licensee or any of its Affiliates. Subject to the foregoing, as between the Parties, Licensee shall
own all right, title and interest to the Product Trademarks in the Territory.

 

		(f)	Ownership of Corporate Names

 

As between the Parties, ArQule
shall retain all right, title and interest in and to its Corporate Names.

 

(g)       Ownership
of Development Data

 

Subject to Clause 2 (GRANT OF
RIGHTS), Licensee shall own Licensee Development Data and ArQule shall own ArQule Development Data.

 

		6.2	Maintenance and Prosecution of Patents

 

		(a)	In General

 

As between the Parties,

 

		(i)	ArQule shall have the sole right, but not the obligation, through counsel of its choice at its
discretion and sole cost, to prepare, file, prosecute and maintain the Compound-Specific Invention Patents, ArQule Patents and
ArQule Invention Patents globally, and Joint Patents outside the Territory, including any related invalidation, appeals of invalidation,
interference, re-issuance, re-examination, patent term extension and opposition proceedings with respect thereto; and

 

    	 	33	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(ii)	Licensee shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain
the Licensee Patents and Licensee Invention Patents globally, and Joint Patents in the Territory, including any related invalidation,
interference, re-issuance, re-examination, patent term extension and opposition proceedings with respect thereto, worldwide, in
each case, at its sole cost and expense and through counsel of its choice.

 

		(iii)	For purposes of this Clause 6.2 (Maintenance and Prosecution of Patents), the Party prosecuting,
maintaining or undertaking other related activities pursuant to the foregoing sentence with respect to a Patent shall be the Prosecuting
Party. The Prosecuting Party shall periodically inform the other Party of all material steps with regard to the preparation,
filing, prosecution and maintenance of the Compound-Specific Invention Patents, ArQule Patents, Licensee Patents and Joint Patents,
as applicable, in the Territory, including by providing the non-Prosecuting Party with a copy of material communications to and
from any patent authority in the Territory regarding such Patents and by providing the non-Prosecuting Party drafts of any material
filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such filings
or responses so as to allow for a reasonable opportunity for the non-Prosecuting Party to review and comment thereon. The Prosecuting
Party shall consider in good faith the requests and suggestions of the non-Prosecuting Party with respect to such drafts and with
respect to strategies for filing and prosecuting such Patents in the Territory, including, but not limited to, by taking into consideration
the commercial strategy of Licensee in the Licensed Territory. If the Prosecuting Party decides not to prepare, file, prosecute
or maintain an Compound-Specific Invention Patent, or ArQule Patent in the Territory, or a Licensee Patent or a Joint Patent in
the Territory or in any country outside the Territory, the Prosecuting Party shall provide reasonable prior written notice to the
non-Prosecuting Party of such intention and the non-Prosecuting Party shall thereupon have the right, in its sole discretion, to
assume the Control and direction of the preparation, filing, prosecution and maintenance of such Compound-Specific Invention Patent,
Licensee Patent, ArQule Patent or Joint Patent at its sole cost and expense, whereupon the non-Prosecuting Party shall be deemed
the Prosecuting Party with respect to such Patent.

 

		(b)	Co-operation

 

The non-Prosecuting Party shall,
and shall cause its Affiliates to, Assist and co-operate with the Prosecuting Party, as the Prosecuting Party may reasonably request
from time to time, in the preparation, filing, prosecution and maintenance of the Compound-Specific Invention Patents, ArQule Patents,
Joint Patents and the Licensee Patents under this Agreement, including that the non-Prosecuting Party shall, and shall ensure that
its Affiliates, (i) offer its comments, if any, promptly, (ii) provide access to relevant documents and other evidence and make
its employees available at reasonable business hours and (iii) provide the Prosecuting Party, upon its request, with copies of
any patentability search reports generated by its patent counsel with respect to the Compound-Specific Invention Patents, ArQule
Patents, Joint Patents or the Licensee Patents, including relevant Third Party patents and patent applications located; provided,
however, that neither Party shall be required to provide legally privileged information with respect to such intellectual property
unless and until procedures reasonably acceptable to such Party are in place to protect such privilege); and provided, further,
that the Prosecuting Party shall reimburse the non-Prosecuting Party for its reasonable and verifiable out-of-pocket costs and
expenses incurred in connection therewith. Each Party will use reasonable efforts to make available to the other its authorized
attorneys, agents or representatives, or such of its employees as are reasonably necessary to Assist the other Party in exercising
its rights described under this Clause 6.2 (Maintenance and Prosecution of Patents). Each Party will sign, or will use reasonable
efforts to have signed, all legal documents as are reasonably necessary to prosecute and maintain Patents in accordance with this
Clause 6.2 (Maintenance and Prosecution of Patents). Each Party shall provide the other Party all reasonable assistance and cooperation
in the Patent prosecution efforts described above in this Clause 6.2 (Maintenance and Prosecution of Patents), including by providing
any necessary powers of attorney, oaths, declarations, or assignments, and executing any other required documents or instruments
for such Patent prosecution efforts.

 

    	 	34	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(c)	Patent Term Extension and Supplementary Protection Certificate

 

The Parties, through their representatives
on the JDC, shall discuss any decisions regarding whether to apply for patent term extensions in the Territory or any other extensions
that are now or become available in the future, wherever applicable, for the Compound-Specific Invention Patents, ArQule Patents,
Joint Patents and any Licensee Patents, and with respect to the Licensed Compound and the Licensed Products in the Territory, in
each case including whether or not to do so; provided that (i) ArQule shall consult with Licensee to determine the course
of action with respect to such filings, and (ii) Licensee shall provide prompt and reasonable assistance, as requested by ArQule,
including by taking such action as patent holder as is required under any Applicable Law to obtain such extension or supplementary
protection certificate and (iii) subject to the foregoing, ArQule shall have the right to make the final decision with respect
to any matters covered by this Clause 6.2(c) (Patent Term Extension and Supplementary Protection Certificate) outside the Territory,
and the Parties will mutually agree upon the final decision with respect to any matters covered
by this Clause 6.2(c) (Patent Term Extension and Supplementary Protection Certificate) in the Territory. If under Applicable Law,
Licensee is required to file such a patent term extension of supplementary protection certificate or equivalence thereof under
its own name, then ArQule shall promptly provide assistance to Licensee to enable such filing.

 

		(d)	Common Ownership Under Joint Research Agreements

 

Notwithstanding anything to the
contrary in this Clause 6 (INTELLECTUAL PROPERTY), neither Party shall have the right to make an election under 35 U.S.C. 102(c)
when exercising its rights under this Clause 6 (INTELLECTUAL PROPERTY) without the prior written consent of the other Party. With
respect to any such permitted election, the Parties shall co-ordinate their activities with respect to any submissions, filings
or other activities in support thereof. The Parties acknowledge and agree that this Agreement is a "joint research agreement"
as defined in 35 U.S.C. 100(h).

 

		(e)	Patent Listings

 

As between the Parties, Licensee
shall have the sole right to make decisions regarding patent listing or equivalents thereof and Licensee shall have the right to
make all filings with Regulatory Authorities in the Territory with respect to the ArQule Patents and Joint Patents or other international
equivalents; provided that Licensee shall consult with ArQule to determine the course of action with respect to such filings.

 

		6.3	Enforcement of Patents

 

		(a)	Notice

 

Each Party shall promptly notify
the other Party in writing of (i) any alleged or threatened infringement of the ArQule Patents, ArQule Invention Patents, Compound-Specific
Invention Patents, Joint Patents or Licensee Patents in any jurisdiction in the Territory or (ii) any certification in the Territory
that is similar to a Hatch-Waxman certification or notice in the US, in each case ((i) and (ii)) of which such Party becomes aware
(an Infringement).

 

    	 	35	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(b)	Enforcement of Patents

 

As between the Parties, (i) ArQule
shall have the first right, but not the obligation, to prosecute any Infringement with respect to the ArQule Patents, ArQule Invention
Patents, and Compound-Specific Invention Patents globally, and Joint Patents outside the Territory, including as a defense or counterclaim
in connection with any Third Party Infringement Claim, at ArQule's sole cost and expense, using counsel of ArQule's choice and
(ii) Licensee shall have the sole right, but not the obligation, to prosecute Infringement with respect to the Licensee Patents
and Licensee Invention Patents globally, and Joint Patents in the Territory, including as a defense or counterclaim in connection
with any Third Party Infringement Claim, at Licensee's sole cost and expense, using counsel of its choice. For purposes of this
Clause 6.3 (Enforcement of Patents), the Party prosecuting any Infringement pursuant to the foregoing sentence with respect to
a Patent shall be the Enforcing Party. In the event ArQule prosecutes any such Infringement in the Field in the Territory,
Licensee shall have the right to join as a party to such claim, suit or proceeding and participate with its own counsel at its
sole cost and expense; provided that ArQule shall retain Control of the prosecution of such claim, suit or proceeding, including
the response to any defense or defense of any counterclaim raised in connection therewith. In the event Licensee prosecutes any
such Infringement in the Field in the Territory, ArQule shall have the right to join as a party to such claim, suit or proceeding
and participate with its own counsel at its sole cost and expense; provided that Licensee shall retain Control of the prosecution
of such claim, suit or proceeding, including the response to any defense or defense of any counterclaim raised in connection therewith.
If the Enforcing Party or its designee does not take commercially reasonable steps to prosecute an Infringement (A) within
*** days following the first notice provided above with respect to such Infringement or (B) provided such date occurs
after the first such notice of such Infringement is provided, *** Business Days before the time limit, if any, set forth in appropriate
laws and regulations for filing of such actions, whichever comes first, then (I) the Enforcing Party shall so notify the non-Enforcing
Party and (II) the non-Enforcing Party may prosecute such alleged or threatened infringement at its sole cost and expense, whereupon
the non-Enforcing Party shall be deemed the Enforcing Party with respect to such Infringement.

 

		(c)	Co-operation

 

The Parties agree to co-operate
fully in any Infringement action pursuant to this Clause 6.3 (Enforcement of Patents), including by making the inventors, applicable
records and documents (including laboratory notebooks) with respect to the relevant Patents available to the Enforcing Party upon
the Enforcing Party's request. With respect to an action Controlled by the applicable Enforcing Party, the other Party shall, and
shall cause its Affiliates to, Assist and co-operate with the Enforcing Party, as the Enforcing Party may reasonably request from
time to time, in connection with its activities set forth in this Clause 6.3 (Enforcement of Patents), including where necessary,
furnishing a power of attorney solely for such purpose or joining in, or being named as a necessary party to, such action, providing
access to relevant documents and other evidence and making its employees available at reasonable business hours; provided
that the Enforcing Party shall reimburse such other Party for its reasonable and verifiable out-of-pocket costs and expenses incurred
in connection therewith. Unless otherwise set forth herein, the Enforcing Party shall have the right to settle such claim; provided
that neither Party shall have the right to settle any Infringement litigation under this Clause 6.3 (Enforcement of Patents) in
a manner that has a material adverse effect on the rights or interest of the other Party or in a manner that imposes any costs
or liability on or involves any admission of wrongdoing by, the other Party, without the express written consent of such other
Party (which consent shall not be unreasonably withheld, conditioned or delayed). In connection with any activities with respect
to an Infringement action prosecuted by the applicable Enforcing Party pursuant to this Clause 6.3 (Enforcement of Patents) involving
Patents Controlled by or licensed under Clause 2 (GRANTS OF RIGHTS) to the other Party, the Enforcing Party shall (i) consult with
the other Party as to the strategy for the prosecution of such claim, suit or proceeding, (ii) consider in good faith any comments
from the other Party with respect thereto and (iii) keep the other Party reasonably informed of any material steps taken and provide
copies of all material documents filed, in connection with such action.

 

    	 	36	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(d)	Recovery

 

Except as otherwise agreed by
the Parties in connection with a cost-sharing arrangement, any recovery realized as a result of such litigation described above
in this Clause 6.3 (Enforcement of Patents) (whether by way of settlement or otherwise) shall be first allocated to reimburse the
Parties for their costs and expenses in making such recovery (which amounts shall be allocated pro rata if insufficient to cover
the totality of such expenses). Any remainder after such reimbursement is made shall be retained by the Enforcing Party; provided,
however, that to the extent that any award or settlement (whether by judgment or otherwise) with respect to an ArQule Patent,
Compound-Specific Invention Patent, Licensee Patent or Joint Patent is attributable to loss of sales or profits with respect to
a Licensed Product, such award shall be deemed Net Sales in the Calendar Quarter in which payment is actually received by Licensee.

 

		6.4	Infringement Claims by Third Parties

 

If the Exploitation of a Licensed
Product in the Territory pursuant to this Agreement results in, or is reasonably expected to result in, any claim, suit or proceeding
by a Third Party alleging Infringement by Licensee or any of its Affiliates or its or their Sublicensees, distributors or customers
(a Third Party Infringement Claim), including any defense or counterclaim in connection with an Infringement action initiated
pursuant to this Clause 6.4 (Infringement Claims by Third Parties), the Party first becoming aware of such alleged Infringement
shall promptly notify the other Party thereof in writing. As between the Parties, Licensee shall be responsible for defending any
such claim, suit or proceeding at its sole cost and expense, using counsel of Licensee's choice. ArQule may participate in any
such claim, suit or proceeding with counsel of its choice at its sole cost and expense; provided that Licensee shall retain
the right to Control such claim, suit or proceeding. ArQule shall, and shall cause its Affiliates to, Assist and co-operate with
Licensee, as Licensee may reasonably request from time to time, in connection with its activities set forth in this Clause 6.4
(Infringement Claims by Third Parties), including where necessary, furnishing a power of attorney solely for such purpose or joining
in, or being named as a necessary party to, such action, providing access to relevant documents and other evidence and making its
employees available at reasonable business hours; provided, further, that Licensee shall reimburse ArQule for its reasonable
and verifiable out-of-pocket costs and expenses incurred in connection therewith. Licensee shall keep ArQule reasonably informed
of all material Developments in connection with any such claim, suit or proceeding. Licensee agrees to provide ArQule with copies
of all material pleadings filed in such action and to allow ArQule reasonable opportunity to participate in the defense of the
claims. Any damages, or awards, including royalties incurred or awarded in connection with any Third Party Infringement Claim defended
under this Clause 6.4 (Infringement Claims by Third Parties) shall be borne by Licensee, subject to Clause 5.4(d) (Reductions)
in the case of royalties. Notwithstanding the above, Licensee shall not enter into any settlement of any such claim without the
prior written consent of ArQule if such settlement would require ArQule to be subject to an injunction or to make any monetary
payment to Licensee or any Third Party, or admit any wrongful conduct by ArQule or its Affiliates, or would limit or restrict the
claims of or admit any invalidity and/or unenforceability of any of the Patents Controlled by ArQule.

 

    	 	37	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		6.5	Invalidity or Unenforceability Defenses or Actions

 

Each Party shall promptly notify
the other Party in writing of any alleged or threatened assertion of invalidity or unenforceability of any of the ArQule Patents,
Compound-Specific Invention Patents, Joint Patents or Licensee Patents by a Third Party and of which such Party becomes aware.
As between the Parties, (a) ArQule shall have the first right, but not the obligation, to defend and Control the defense of the
validity and enforceability of the ArQule Patents and Compound-Specific Invention Patents globally, and the Joint Patents outside
the Territory, at its sole cost and expense, using counsel of ArQule' s choice and (b) Licensee shall have the first right, but
not the obligation, to defend and Control the defense of the validity and enforceability of the Licensee Patents globally and the
Joint Patents in the Territory, at its sole cost and expense, using counsel of Licensee's choice, including, in each case ((a)
and (b)), when such invalidity or unenforceability is raised as a defense or counterclaim in connection with an Infringement action
initiated pursuant to Clause 6.3 (Enforcement of Patents). For purposes of this Clause 6.5 (Invalidity or Unenforceability Defenses
or Actions), the Party defending and controlling the defense of the validity and enforceability pursuant to the foregoing sentence
with respect to a Patent shall be the Controlling Party. With respect to any such claim, suit or proceeding in the Territory,
the non-Controlling Party may participate in such claim, suit or proceeding with counsel of its choice at its sole cost and expense;
provided that the Controlling Party shall retain Control of the defense in such claim, suit or proceeding. If the Controlling
Party or its designee elects not to defend or Control the defense of the applicable Patents in a suit brought in the Territory,
or a suit involving the Joint Patents outside the Territory, or otherwise fails to initiate and maintain the defense of any such
claim, suit or proceeding, then the Controlling Party shall notify the non-Controlling Party at least *** Business Days before
the time limit, if any, set forth in appropriate laws and regulations for defending such actions, and the non-Controlling Party
may conduct and Control the defense of any such claim, suit or proceeding at its sole cost and expense. The non-Controlling Party
in such an action shall, and shall cause its Affiliates to, Assist and co-operate with the Controlling Party, as such Controlling
Party may reasonably request from time to time in connection with its activities set forth in this Clause 6.5 (Invalidity or Unenforceability
Defenses or Actions), including where necessary, furnishing a power of attorney solely for such purpose or joining in, or being
named as a necessary party to, such action, providing access to relevant documents and other evidence and making its employees
available at reasonable business hours; provided that the Controlling Party shall reimburse the non-Controlling Party for
its reasonable and verifiable out-of-pocket costs and expenses incurred in connection therewith. In connection with any activities
with respect to a defense, claim or counterclaim relating to the ArQule Patents, Compound-Specific Invention Patents, Licensee
Patents or Joint Patents pursuant to this Clause 6.5 (Invalidity or Unenforceability Defenses or Actions), the Controlling Party
shall (i) consult with the non-Controlling Party as to the strategy for such activities, (ii) consider in good faith any comments
from the non-Controlling Party and (iii) keep the non-Controlling Party reasonably informed of any material steps taken and provide
copies of all material documents filed, in connection with such defense, claim or counterclaim.

 

		6.6	Product Trademarks

 

		(a)	Notice

 

Each Party shall provide to the
other Party prompt written notice of any actual or threatened Infringement of the Product Trademarks in the Territory and of any
actual or threatened claim that the use of the Product Trademarks in the Territory violates the rights of any Third Party, in each
case, of which such Party becomes aware.

 

		(b)	Prosecution of Product Trademarks

 

Licensee shall be responsible
for the registration, prosecution and maintenance of the Product Trademarks using counsel of its own choice. All costs and expenses
of registering, prosecuting and maintaining the Product Trademarks shall be borne solely by Licensee.

 

		(c)	Enforcement of Product Trademarks

 

Licensee shall have the sole
right to take such action as Licensee deems necessary against a Third Party based on any alleged, threatened or actual Infringement,
dilution, misappropriation or other violation of or unfair trade practices or any other like offense relating to, the Product Trademarks
by a Third Party in the Territory at its sole cost and expense and using counsel of its own choice. Licensee shall retain any damages
or other amounts collected in connection therewith.

 

    	 	38	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(d)	Third Party Claims

 

Licensee shall have the sole
right to defend against and settle any alleged, threatened or actual claim by a Third Party that the use or registration of the
Product Trademarks in the Territory infringes, dilutes, misappropriates or otherwise violates any Trademark or other right of that
Third Party or constitutes unfair trade practices or any other like offense or any other claims as may be brought by a Third Party
against a Party in connection with the use of the Product Trademarks with respect to a Licensed Product in the Territory at its
sole cost and expense and using counsel of its own. Any damages, or awards, including royalties incurred or awarded in connection
with any such claim defended under this Clause 6.6(d) (Third Party Claims) shall be borne by Licensee.

 

		(e)	Co-operation

 

ArQule shall, and shall cause
its Affiliates to, reasonably Assist and co-operate with Licensee, as Licensee may reasonably request from time to time, in connection
with its activities set forth in this Clause 6.6(e) (Co-operation), including where necessary, furnishing a power of attorney solely
for such purpose or joining in, or being named as a necessary party to, such action, providing access to relevant documents and
other evidence and making its employees available at reasonable business hours; provided that Licensee shall reimburse ArQule
for its and its Affiliates' reasonable and verifiable costs and expenses incurred in connection therewith.

 

		7.	Confidentiality and Non-Disclosure

 

		7.1	Confidentiality Obligations

 

At all times during
the Term and for a period of  ten (10) years following termination or expiration hereof in its entirety, each Party shall and
shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a
Third Party and not use, directly or indirectly, for any purpose, any Confidential Information furnished or otherwise made
known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted
by the terms of this Agreement. Confidential Information means any technical, business or other Information provided
by or on behalf of one Party to the other Party in connection with this Agreement, whether prior to, on or after the
Effective Date, including Information relating to the terms of this Agreement (subject to Clause 7.2 (Permitted Disclosure),
Clause 7.4 (Public Announcements) and Clause 7.5 (Publications)), Information relating to the Licensed Compound or any
Licensed Product (including any clinical data and Regulatory Documentation), any Development or Commercialization of the
Licensed Compound or any Licensed Product, any know-how with respect thereto Developed by or on behalf of the disclosing
Party or its Affiliates (including Licensee Know-How and ArQule Know-How, as applicable) or the scientific, regulatory or
business affairs or other activities of either Party. Notwithstanding the foregoing, Joint Inventions and the terms of this
Agreement shall be deemed to be the Confidential Information of both Parties and both Parties shall be deemed to be the
receiving Party and the disclosing Party with respect thereto. In addition, notwithstanding the foregoing, the
confidentiality and non-use obligations under this Clause 7.1 (Confidentiality Obligations) with respect to any Confidential
Information shall not include any Information that:

 

		(a)	is or hereafter becomes part of the public domain by public use, publication, general knowledge
or the like through no breach of this Agreement by the receiving Party;

 

		(b)	can be demonstrated by documentation or other competent proof to have been in the receiving Party's
possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such Information;
provided that the foregoing exception shall not apply with respect to Joint Inventions;

 

		(c)	is subsequently received by the receiving Party from a Third Party who is not bound by any obligation
of confidentiality with respect to such Information;

 

    	 	39	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(d)	has been published by a Third Party or otherwise enters the public domain through no fault of the
receiving Party in breach of this Agreement; or

 

		(e)	can be demonstrated by documentation or other competent evidence to have been independently developed
by or for the receiving Party without reference to the disclosing Party's Confidential Information; provided that the foregoing
exception shall not apply with respect to Joint Inventions.

 

Specific aspects or details of
Confidential Information shall not be deemed to be within the public domain or in the possession of the receiving Party merely
because the Confidential Information is embraced by more general Information in the public domain or in the possession of the receiving
Party.

 

		7.2	Permitted Disclosures

 

Each Party may disclose Confidential
Information to the extent that such disclosure is:

 

		(a)	made in response to a valid order of a court of competent jurisdiction or other supra-national,
federal, national, regional, state, provincial and local governmental or regulatory body of competent jurisdiction or, if in the
reasonable opinion of the receiving Party's legal counsel, such disclosure is otherwise required by law, including by reason of
filing with securities regulators; provided, however, that the receiving Party shall first have given notice to the disclosing
Party and given the disclosing Party a reasonable opportunity to quash such order or to obtain a protective order or confidential
treatment requiring that the Confidential Information and documents that are the subject of such order be held in confidence by
such court or agency or, if disclosed, be used only for the purposes for which the order was issued; and provided, further,
that the Confidential Information disclosed in response to such court or governmental order shall be limited to that information
which is legally required to be disclosed in response to such court or governmental order, as advised by outside counsel;

 

		(b)	made by or on behalf of the receiving Party to the Regulatory Authorities as required in connection
with any filing, application or request for Regulatory Approval; provided, however, that reasonable measures shall be taken
to assure confidential treatment of such Information to the extent practicable and consistent with Applicable Law;

 

		(c)	made by or on behalf of the receiving Party to a patent authority as may be reasonably necessary
or useful for purposes of obtaining or enforcing a Patent; provided, however, that reasonable measures shall be taken to
assure confidential treatment of such Information, to the extent such protection is available; or

 

		(d)	made by or on behalf of the receiving Party to (i) actual or potential investors, acquirers, licensees
and other financial or commercial partners for the purpose of evaluating or carrying out an actual or potential investment, acquisition
or collaboration, public offering, merger or acquisition of a Party or its Affiliates, or sale of all or substantially all of its
business to which this Agreement relates, provided that any such Third Party agrees to be bound by confidentiality and non-use
obligations that are no less stringent than those contained in this Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE) (except to the
extent that a shorter confidentiality period is customary in the industry), or (ii) any Third Party that is or may be engaged by
a Party to perform services as permitted under this Agreement as necessary to enable such Third Party to perform such services
including a Party’s directors, independent contractors, consultants, attorneys, independent accountants and financial advisors,
provided that such persons agrees to be bound by confidentiality and non-use obligations that are no less stringent than
those contained in this Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE) (with a duration of confidentiality and non-use obligations
as appropriate that is no less than *** years from the date of disclosure).

 

    	 	40	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		7.3	Use of Name

 

Except as expressly provided
herein, neither Party shall mention or otherwise use the name, logo or Trademark of the other Party or any of its Affiliates or
any of its or their (sub)licensees (or Sublicensees) (or any abbreviation or adaptation thereof) in any publication, press release,
marketing and promotional material or other form of publicity without the prior written approval of such other Party. The restrictions
imposed by this Clause 7.3 (Use of Name) shall not prohibit (a) either Party from making any disclosure identifying the other Party
to the extent required in connection with its exercise of its rights or obligations under this Agreement and (b) either Party from
making any disclosure identifying the other Party that is required by Applicable Law or the rules of a stock exchange on which
the securities of the disclosing Party are listed (or to which an application for listing has been submitted). Notwithstanding
the above, each Party and its Affiliates may disclose on its website and in its promotional materials that the other Party is a
development partner of such Party and may utilize the other Party’s name and logo in conjunction with such disclosure.

 

		7.4	Public Announcements

 

		(a)	The Parties will mutually agree on the content of a joint press release to announce the transaction
contemplated by this Agreement, to be released at a mutually agreed time that is consistent with ArQule’s obligations to
disclose material agreements under Form 8-K. Neither Party shall issue any other public announcement, press release or other public
disclosure regarding this Agreement or its subject matter without the other Party's prior written consent, such consent not to
be unreasonably withheld, delayed or conditioned, except for any such disclosure that is, in the opinion of the disclosing Party's
counsel, required by Applicable Law or the rules of a stock exchange on which the securities of the disclosing Party are listed
(or to which an application for listing has been submitted).

 

		(b)	In the event a Party is, in the opinion of its counsel, required by Applicable Law or the rules
of a stock exchange on which its securities are listed (or to which an application for listing has been submitted) to make such
a public disclosure, such Party shall (i) submit the proposed disclosure in writing to the other Party as far in advance as reasonably
practicable (and in no event less than *** Business Days prior to the anticipated date of disclosure) so as to provide a reasonable
opportunity to comment thereon, (ii) consult and coordinate with the other Party with respect to the preparation and submission
of a confidential treatment request for this Agreement and (iii) in good faith consider incorporating such comments. Notwithstanding
the foregoing, such Party will have the right to make such disclosure at the time and in the manner reasonably determined by its
counsel to be required by Applicable Laws or such securities exchange.

 

		(c)	Neither Party shall be required to seek the permission of the other Party to repeat any information
regarding the terms of this Agreement or any amendment hereto that has already been publicly disclosed by such Party or by the
other Party, in accordance with this Clause 7.4 (Public Announcements); provided that such Information remains accurate
as of such time and provided the frequency and form of such disclosure are reasonable.

 

    	 	41	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		7.5	Publications

 

The Parties shall discuss the
publication strategy for the publication of scientific papers, abstracts, meeting presentations, publicly available clinical trial
or regulatory data submissions to governments (and including websites similar to www.clinicaltrials.gov) and other disclosure of
the results of the studies carried out under this Agreement, taking into consideration the Parties’ interest in publishing
the results of the development activities to obtain recognition within the scientific community and to advance the state of scientific
knowledge, and the need to protect Confidential Information, intellectual property rights and other business interests of the Parties.
Each Party shall provide the other Party with the opportunity to review and comment on any proposed publication that pertains to
the Licensed Compound or Licensed Products, and shall endeavour to provide such other Party at least thirty (30) days to review
such proposed publication prior to its intended submission for publication. The Party seeking to publish shall consider in good
faith the comments provided by the other Party and shall comply with such other Party’s request to: (a) remove any and all
Confidential Information of such other Party from such proposed publication; and (b) delay the submission for a period up to ***
days as may be reasonably necessary to seek patent protection for the information disclosed in the proposed publication.

 

		7.6	Return of Confidential Information

 

Upon the effective date of the
expiration or termination of this Agreement for any reason, either Party may request in writing, and the non-requesting Party shall,
with respect to Confidential Information to which such non-requesting Party does not retain rights under the surviving provisions
of this Agreement, at the requesting Party's election, (a) promptly destroy all copies of such Confidential Information in
the possession or Control of the non-requesting Party and confirm such destruction in writing to the requesting Party or (b) promptly
deliver to the requesting Party, at the non-requesting Party's sole cost and expense, all copies of such Confidential Information
in the possession or Control of the non-requesting Party. Notwithstanding the foregoing, the non-requesting Party shall be permitted
to retain such Confidential Information (i) to the extent necessary or useful for purposes of performing any continuing obligations
or exercising any ongoing rights hereunder and, in any event, a single copy of such Confidential Information for archival purposes
and (ii) any computer records or files containing such Confidential Information that have been created solely by such non-requesting
Party's automatic archiving and back-up procedures, to the extent created and retained in a manner consistent with such non-requesting
Party's standard archiving and back-up procedures, but not for any other uses or purposes. All Confidential Information retained
under this Clause 7.6 (Return of Confidential Information) shall continue to be subject to the terms of this Agreement for the
period set forth in Clause 7.1 (Confidentiality Obligations).

 

		7.7	Privileged Communications

 

In furtherance of this Agreement,
it is expected that the Parties may, from time to time, disclose to one another privileged communications with counsel, including
opinions, memoranda, letters and other written, electronic and verbal communications. Such disclosures are made with the understanding
that they shall remain confidential in accordance with this Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE), that they will not be
deemed to waive any applicable attorney-client or attorney work product or other privilege and that they are made in connection
with the shared community of legal interests existing between ArQule and Licensee, including the community of legal interests in
avoiding infringement of any valid, enforceable patents of Third Parties and maintaining the validity of the ArQule Patents, Licensee
Patents and Joint Patents. In the event of any litigation (or potential litigation) with a Third Party related to this Agreement
or the subject matter hereof, the Parties shall, upon either Party's request, enter into a reasonable and customary joint defense
or common interest agreement. In any event, each Party shall consult in a timely manner with the other Party before engaging in
any conduct (eg, producing Information or documents) in connection with litigation or other proceedings that could conceivably
implicate privileges maintained by the other Party. Notwithstanding anything contained in this Clause 7.7 (Privileged Communications),
nothing in this Agreement shall prejudice a Party's ability to take discovery of the other Party in disputes between them relating
to the Agreement and no information otherwise admissible or discoverable by a Party shall become inadmissible or immune from discovery
solely by this Clause 7.7 (Privileged Communications).

 

    	 	42	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		8.	Representations and Warranties

 

		8.1	Mutual Representations and Warranties

 

ArQule and Licensee each represents
and warrants to the other, as of the Effective Date, and covenants, that:

 

		(a)	It is a corporation duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization and has all requisite power and authority, corporate or otherwise, to execute, deliver and perform
under this Agreement;

 

		(b)	The execution and delivery of this Agreement and the performance by it of the transactions contemplated
hereby have been duly authorized by all necessary corporate action and do not violate:

 

		(i)	such Party's charter documents, bylaws or other organizational documents;

 

		(ii)	in any material respect, any agreement, instrument or contractual obligation to which such Party
is bound;

 

		(iii)	any requirement of any Applicable Law; or

 

		(iv)	any order, writ, judgment, injunction, decree, determination or award of any court or governmental
agency presently in effect applicable to such Party;

 

		(c)	This Agreement is a legal, valid and binding obligation of such Party enforceable against it in
accordance with its terms and conditions, subject to the effects of bankruptcy, insolvency or other laws of general application
affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general
principles of equity (whether enforceability is considered a proceeding at law or equity);

 

		(d)	It is not under any obligation, contractual or otherwise, to any Person that conflicts with or
is inconsistent in any material respect with the terms of this Agreement or that would impede the diligent and complete fulfilment
of its obligations hereunder; and

 

		(e)	Neither it nor any of its Affiliates has been debarred or is subject to debarment and neither it
nor any of its Affiliates will use in any capacity, in connection with the services to be performed under this Agreement, any Person
who has been debarred pursuant to Section 306 of the FFDCA or who is the subject of a conviction described in such section. It
will inform the other Party in writing promptly if it or any such Person who is performing services hereunder is debarred or is
the subject of a conviction described in Section 306 or if any action, suit, claim, investigation or legal or administrative proceeding
is pending or, to the best of its or its Affiliates' Knowledge, is threatened, relating to the debarment or conviction of it or
any such Person performing services hereunder.

 

		8.2	Additional Representations and Warranties of ArQule

 

ArQule further represents and
warrants to Licensee, as of the Effective Date, that:

 

		(a)	ArQule Controls the Existing Patents and has the right to grant the licenses and sublicenses specified
herein;

 

		(b)	ArQule has not received any written claim or demand alleging that (i) the Existing Patents
or the ArQule Know-How are invalid or unenforceable or (ii) the Development or Commercialization of the Licensed Compound
as contemplated herein infringes any Patent owned by any Third Party and to ArQule’s Knowledge, there is no reasonable basis
for any such claim or demand by any Third Party;

 

    	 	43	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(c)	to ArQule's Knowledge, no Person is infringing or threatening to infringe the Existing Patents;

 

		(d)	ArQule is not subject to any agreement with a Third Party that includes a royalty or similar payment
obligation to, or other restriction or limitation in favor of, such Third Party (including, for this purpose, to current or former
officers, directors, employees, consultants or personnel of ArQule or any predecessor) with respect to (i) its rights to practice
the ArQule Technology in the Territory or (ii) the Development or Commercialization of the Licensed Compound or any Licensed Product
in the Territory;

 

		(e)	to ArQule's Knowledge, the conception, development, and reduction to practice of the ArQule Patents
and ArQule Know-How existing as of the Effective Date have not constituted or involved the misappropriation of trade secrets or
other rights or property of any Person;

 

		(f)	no ArQule Patents are subject to, or were developed pursuant to, any funding agreement with any
government or government agency;

 

		(g)	ArQule is not in material breach of any provisions of any agreements with Third Parties relating
to the ArQule Patents or ArQule Know-How, in each case, in a manner that is reasonably likely to affect the rights of the other
Party hereunder or adversely affect the Development, Manufacturing, Regulatory Approval, or Commercialization of any Licensed Product
hereunder;

 

		(h)	ArQule has not received any written or oral claim of ownership, inventorship or patent Infringement
from any Third Party (including by current or former officers, directors, employees, consultants, or personnel of ArQule or any
predecessor) with respect to the ArQule Technology;

 

		(i)	no claim or litigation has been brought or threatened by any Person alleging, and ArQule is not
aware, that any of the ArQule Patents or the ArQule Know-How are invalid or unenforceable; and

 

		(j)	to ArQule’s Knowledge, it and its Affiliates have not violated any material Anti-Corruption
Laws with respect to the Territory.

 

		8.3	DISCLAIMER OF WARRANTIES

 

EXCEPT FOR THE EXPRESS WARRANTIES
SET FORTH HEREIN, NEITHER PARTY MAKES ANY REPRESENTATIONS OR GRANTS ANY WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION
OF LAW, BY STATUTE OR OTHERWISE AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL OR EXPRESS
OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO
THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES.

 

    	 	44	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		8.4	Anti-Bribery and Anti-Corruption Compliance

 

		(a)	Each Party will conduct its business in accordance with Applicable Law. By signing this Agreement,
each Party agrees to conduct its activities under this Agreement in a manner that is consistent with Applicable Law, including
the U.S. Foreign Corrupt Practices Act, the UK Bribery Act 2010, and the relevant provisions of the People's Republic of China
Criminal Law and People's Republic of China Anti-Unfair Competition Law, each as amended, and any other applicable anti-corruption
laws and laws for the prevention of fraud, racketeering, or money laundering (collectively, Anti-Corruption Laws).

 

		(b)	Each Party will not, directly or indirectly, pay, offer or promise to pay, or authorize the payment
of any money, or give, offer or promise to give, or authorize the giving of anything of value (collectively, a Prohibited Payment)
to any Government Official where such Prohibited Payment would constitute a violation of any Anti-Corruption Law. In addition,
regardless of legality, each Party will make no Prohibited Payment, directly or indirectly, to any Government Official if such
Prohibited Payment is for the purpose of influencing decisions or actions with respect to the subject matter of this Agreement
or any other aspect of the other Party's business. Each Party acknowledges and agrees that none of it, or any of its Affiliates
or its or their respective officers, directors, employees, agents and representatives (collectively, Authorized Representatives)
is authorized to waive compliance with the provisions of this Clause 8.4 (Anti-Bribery and Anti-Corruption Compliance) and that
each Party will be solely responsible for its compliance with the provisions of this Clause 8.4 (Anti-Bribery and Anti-Corruption
Compliance) and the Anti-Corruption Laws irrespective of any act or omission of the other Party or any of its Affiliates, Sublicensees
or its or their respective Authorized Representatives. Each Party's failure to abide by the provisions of this Clause 8.4 (Anti-Bribery
and Anti-Corruption Compliance) shall be deemed a material breach of this Agreement.

 

		9.	Indemnity; INSURANCE

 

		9.1	Indemnification of ArQule

 

Licensee shall indemnify ArQule,
its Affiliates, its or their (sub)licensees and its and their respective directors, officers, employees and agents and defend and
save each of them harmless, from and against any and all losses, damages, liabilities, costs and expenses (including reasonable
attorneys' fees and expenses) (collectively, Losses) in connection with any and all suits, investigations, claims or demands
of Third Parties (collectively, Third Party Claims) arising from or occurring as a result of:

 

		(a)	the material breach by Licensee of this Agreement;

 

		(b)	the gross negligence or wilful misconduct on the part of Licensee or its Affiliates or its or their
Sublicensees or its or their distributors or contractors or its or their respective directors, officers, employees or agents in
performing its or their obligations under this Agreement; or

 

		(c)	the Exploitation by Licensee or any of its Affiliates or its or their Sublicensees or its or their
distributors or contractors of any Licensed Product or the Licensed Compound in the Territory, except, in each case ((a), (b) and
(c)), for those Losses for which ArQule has an obligation to indemnify Licensee pursuant to Clause 9.2 (Indemnification of
Licensee) hereof, as to which Losses each Party shall indemnify the other to the extent of their respective liability.

 

		9.2	Indemnification of Licensee

 

ArQule shall indemnify Licensee,
its Affiliates and their respective directors, officers, employees and agents and defend and save each of them harmless, from and
against any and all Losses in connection with any and all Third Party Claims arising from or occurring as a result of:

 

    	 	45	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(a)	the material breach by ArQule of this Agreement;

 

		(b)	the gross negligence or wilful misconduct on the part of ArQule or its Affiliates or its or their
sublicensees or its or their distributors or contractors or its or their respective directors, officers, employees or agents in
performing its or their obligations under this Agreement; or

 

		(c)	the Exploitation by ArQule or any of its Affiliates or its or their sublicensees or its or their
distributors or contractors of the Licensed Compound or Licensed Products outside the Territory, except, in each case ((a), (b)
and (c)), for those Losses for which Licensee has an obligation to indemnify ArQule pursuant to Clause 9.1 (Indemnification
of ArQule) hereof, as to which Losses each Party shall indemnify the other to the extent of their respective liability for the
Losses.

 

		9.3	Indemnification Procedures

 

		(a)	Notice of Claim

 

All indemnification claims in
respect of a Party, its Affiliates or its or their Sublicensees (or (sub)licensees) or their respective directors, officers, employees
and agents shall be made solely by such Party to this Agreement (the Indemnified Party). The Indemnified Party shall give
the indemnifying Party prompt written notice (an Indemnification Claim Notice) of any Losses or discovery of fact upon which
such Indemnified Party intends to base a request for indemnification under this Clause 9 (INDEMNITY; INSURANCE), but in no event
shall the indemnifying Party be liable for any Losses that result from any delay in providing such notice unless the Indemnified
Party demonstrates actual harm from such delay. Each Indemnification Claim Notice must contain a description of the claim and the
nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party
shall furnish promptly to the indemnifying Party copies of all papers and official documents received in respect of any Losses
and Third Party Claims.

 

		(b)	Control of Defense

 

The indemnifying Party shall
have the right to assume the defense of any Third Party Claim by giving written notice to the Indemnified Party within *** days
after the indemnifying Party's receipt of an Indemnification Claim Notice; provided, that the indemnifying Party expressly
agrees to indemnify the Indemnified Party with respect to such Third Party Claim. The assumption of the defense of a Third Party
Claim by the indemnifying Party shall not be construed as an acknowledgment that the indemnifying Party is liable to indemnify
the Indemnified Party in respect of the Third Party Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses
it may assert against the Indemnified Party's claim for indemnification. Upon assuming the defense of a Third Party Claim, the
indemnifying Party may appoint as lead counsel in the defense of the Third Party Claim any legal counsel selected by the indemnifying
Party; provided, that it obtains the prior written consent of the Indemnified Party (which consent shall not be unreasonably
withheld, conditioned or delayed). In the event the indemnifying Party assumes the defense of a Third Party Claim, the Indemnified
Party shall immediately deliver to the indemnifying Party all original notices and documents (including court papers) received
by the Indemnified Party in connection with the Third Party Claim. Should the indemnifying Party assume the defense of a Third
Party Claim, except as provided in Clause 9.3(c) (Right to Participate in Defense), the indemnifying Party shall not be liable
to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with the analysis,
defense or settlement of the Third Party Claim unless specifically requested in writing by the indemnifying Party. In the event
that it is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified
Party from and against the Third Party Claim, the Indemnified Party shall reimburse the indemnifying Party for any and all reasonable
and verifiable costs and expenses (including attorneys' fees and costs of suit) and any Losses incurred by the indemnifying Party
in accordance with this Clause 9 (INDEMNITY; INSURANCE) in its defense of the Third Party Claim.

 

    	 	46	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(c)	Right to Participate in Defense

 

Any Indemnified Party shall be
entitled to participate in the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided,
however, that such employment shall be at the Indemnified Party's sole cost and expense unless (i) the employment thereof
has been specifically authorized in writing by the indemnifying Party in writing, (ii) the indemnifying Party has failed to assume
the defense and employ counsel in accordance with Clause 9.3(b) (Control of Defense) (in which case the Indemnified Party
shall Control the defense) or (iii) the interests of the indemnitee and the indemnifying Party with respect to such Third
Party Claim are sufficiently adverse to prohibit the representation by the same counsel of both Parties under Applicable Law, ethical
rules or equitable principles (in which case, the Indemnified Party shall Control its defense).

 

		(d)	Settlement

 

With respect to any Losses relating
solely to the payment of money damages in connection with a Third Party Claim and that shall not result in the applicable indemnitee(s)
becoming subject to injunctive or other relief or otherwise adversely affecting the business of the Indemnified Party in any manner
and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify the applicable indemnitee
hereunder, the indemnifying Party shall have the sole right to consent to the entry of any judgment, enter into any settlement
or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate. With
respect to all other Losses in connection with Third Party Claims, where the indemnifying Party has assumed the defense of the
Third Party Claim in accordance with Clause 9.3(b) (Control of Defense), the indemnifying Party shall have authority to consent
to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss; provided, it obtains the prior
written consent of the Indemnified Party (which consent shall not be unreasonably withheld, conditioned or delayed). If the indemnifying
Party does not assume and conduct the defense of a Third Party Claim as provided above, the Indemnified Party may defend against
such Third Party Claim; provided, that the Indemnified Party shall not settle any Third Party Claim without the prior written
consent of the indemnifying Party (which consent shall not be unreasonably withheld, conditioned or delayed).

 

		(e)	Cooperation

 

Regardless of whether the indemnifying
Party chooses to defend or prosecute any Third Party Claim, the Indemnified Party shall and shall cause each indemnitee to, cooperate
in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend
such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith. Such
cooperation shall include access during normal business hours afforded to the indemnifying Party to, and reasonable retention by
the Indemnified Party of, records and Information that are reasonably relevant to such Third Party Claim, and making Indemnified
Parties and other employees and agents available on a mutually convenient basis to provide additional Information and explanation
of any material provided hereunder. The indemnifying Party shall reimburse the Indemnified Party for all of its, its Affiliates'
and its and their (sub)licensees' or their respective directors', officers', employees' and agents', as applicable, reasonable
and verifiable out-of-pocket expenses in connection therewith.

 

		(f)	Expenses

 

Except as provided
above, the costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified Party and its Affiliates
and its and their Sublicensees (or (sub)licensees) and their respective directors, officers, employees and agents, as applicable,
in connection with any claim, shall be reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the
indemnifying Party's right to contest the Indemnified Party's right to indemnification, and subject to refund in the event the
indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party.

 

    	 	47	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		9.4	Insurance

 

Each Party,
at its own expense, will maintain liability insurance (or self-insure) with respect to its activities under this Agreement in an
amount consistent with industry standards. Each Party will provide a certificate of insurance (or evidence of self-insurance) evidencing
such coverage to the other Party upon request. Without limiting the foregoing, during the Term or for such other period of time
specified below, Licensee will maintain on an ongoing basis (a) comprehensive general liability insurance in the minimum amount
of *** dollars ($***) per occurrence and *** dollars ($***) annual aggregate combined single limit for bodily injury and property
damage liability; (b) commencing no later than *** days prior to First Commercial Sale, products liability insurance (including
contractual liability coverage on Licensee’s indemnification obligations under this Agreement) in the amount of at least
*** dollars ($***) per occurrence and as an annual aggregate combined single limit for bodily injury and property damage liability;
and (c) prior to the initiation of any clinical trial, Licensee will secure and maintain in full force and effect clinical trial
insurance in compliance with Applicable Laws in those countries where such clinical trial is conducted. All of such insurance coverage
may be maintained through a self-insurance plan that substantially complies with the foregoing limits and requirements and may
be satisfied through one (1) or more policies, including an umbrella policy; provided, however, that such self-insurance
is determined to be investment quality by a recognized rating agency such as Moody’s or Standard & Poor’s. Not
later than *** days following receipt of written request from a Party, the other Party will provide to the requesting Party a letter(s)
affirming appropriate self-insurance and/or a certificate of insurance evidencing such coverage in accordance with this Agreement.
Each Party will maintain such insurance or self-insurance coverage without interruption during the Term and for a period of ***
years thereafter, and, if applicable, will provide certificates and/or letters evidencing such insurance coverage without interruption
as reasonably requested during the period of time for which such coverage must be maintained. Each Party will be provided at least
*** days’ prior written notice of any cancellation or material decrease in the other Party’s insurance coverage limits
described above. Notwithstanding the foregoing, either Party’s failure to maintain adequate insurance will not relieve that
Party of its obligations set forth in this Agreement.

 

		9.5	Special, Indirect and Other Losses

 

EXCEPT (a) IN THE EVENT OF THE
WILLFUL MISCONDUCT OR FRAUD OF A PARTY OR OF A PARTY'S BREACH OF ITS OBLIGATIONS UNDER CLAUSE 7 (CONFIDENTIALITY AND NON-DISCLOSURE),
or (b) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION
UNDER THIS CLAUSE 9 (INDEMNITY; INSURANCE), NEITHER PARTY NOR ANY OF ITS AFFILIATES OR (SUB)LICENSEES SHALL BE LIABLE IN CONTRACT,
TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES,
OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.

 

		10.	Term and Termination

 

		10.1	Term and Expiration

 

This Agreement shall commence
on the Effective Date and, unless earlier terminated in accordance herewith, shall continue in force and effect until the date
of expiration of the last Royalty Term for the last Licensed Product (such period, the Term). Following the expiration of
the Royalty Term for a Licensed Product, the grants in Clause 2.1 (Grants to Licensee) shall become non-exclusive, fully-paid,
royalty-free, and irrevocable for such Licensed Product.

 

    	 	48	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		10.2	Termination

 

		(a)	Material Breach

 

In the event that either Party
(the Breaching Party) shall be in material breach in the performance of any of its obligations under this Agreement, in
addition to any other right and remedy the other Party (the Non-Breaching Party) may have, the Non-Breaching Party may terminate
this Agreement by providing *** days (or *** days in the event the material breach is a failure to pay amounts due and payable
under this Agreement) (the Notice Period) prior written notice to the Breaching Party, specifying the breach and its claim
of right to terminate (the Termination Notice); provided, that the termination shall not become effective at the
end of the Notice Period if the Breaching Party cures the breach specified in the Termination Notice during the Notice Period (or,
if such default cannot be cured within the Notice Period, if the Breaching Party commences actions to cure such breach within the
Notice Period and thereafter diligently continues such actions), or disputes the existence of such material breach in accordance
with the procedures set forth in Clause 11.5 (Governing Law and Dispute Resolution).

 

		(b)	Termination for Convenience by Licensee

 

Prior to its expiration, this
Agreement may be terminated at any time by Licensee effective upon at least *** days' prior written notice to ArQule for any reason.

 

		(c)	Termination by ArQule

 

If Licensee fails to initiate
a clinical trial that is designed to seek Regulatory Approval for License Product in the Territory by ***, ArQule will have the
right to terminate this Agreement in ArQule’s sole discretion. For purposes of this Clause 10.2(c) (Termination by ArQule)
“initiation” means the first date on which a subject or patient is dosed in such clinical trial.

 

		(d)	Termination for Insolvency

 

In the event that either Party:
(i) files for protection under bankruptcy or insolvency laws, (ii) makes an assignment for the benefit of creditors,
(iii) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not discharged
within *** days after such filing, (iv) proposes a written agreement of composition or extension of its debts, (v) proposes
or is a party to any dissolution or liquidation, (vi) files a petition under any bankruptcy or insolvency act or has any such
petition filed against that is not discharged within *** days of the filing thereof, or (vii) admits in writing its inability
generally to meet its obligations as they fall due in the general course, then such action shall constitute a material breach subject
to Clause 10.2(a) (Material Breach).

 

		(e)	Termination for Challenge

 

Except to the extent the following
is unenforceable under the Applicable Law of a particular jurisdiction where a patent application within the ArQule Patents is
pending or a patent within the ArQule Patents issued, in the event that Licensee or any of its Affiliates Challenges any ArQule
Patents or Licensee or any of its Affiliates Assists a Third Party in initiating a Challenge of any ArQule Patents, such action
shall constitute a material breach subject to Clause 10.2(a) (Material Breach).

 

    	 	49	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		10.3	Consequences of Termination

 

Upon termination of this Agreement,

 

		(a)	except as provided in subsection (h), all rights and licenses granted by ArQule hereunder shall
immediately terminate, including, for clarity, any sublicense granted by Licensee pursuant to Clause 2.3 (Sublicenses);

 

		(b)	except as provided in subsection (h), Licensee shall and hereby does, and shall cause its Affiliates
and its and their Sublicensees to, when and as requested by ArQule, assign to ArQule all of its right, title and interest in and
to: (i) all Regulatory Documentation (including any Regulatory Approvals) applicable to any Licensed Compound or Licensed Products
then owned or Controlled by Licensee or any of its Affiliates; provided, that if any such Regulatory Documentation or Regulatory
Approval is not immediately transferable in a country, Licensee shall provide ArQule with all benefit of such Regulatory Documentation
or Regulatory Approval, as applicable, and such assistance and co-operation as necessary or reasonably requested by ArQule to timely
transfer such Regulatory Documentation or Regulatory Approval, as applicable, to ArQule or its designee or, at ArQule's option,
to enable ArQule to obtain a substitute for such Regulatory Documentation or Regulatory Approval, as applicable, without disruption
to ArQule's Exploitation of the Licensed Compound or applicable Licensed Product(s) and (ii) all preclinical and clinical data
and all other supporting data, including CMC Data and pharmacology, toxicology, chemistry and biology data, in Licensee’s
Control as of the effective date of such termination related to, and to the extent necessary or reasonably useful for ArQule to
continue the Development, Manufacture and/or Commercialization of, the Licensed Compound and any Licensed Products;

 

		(c)	except as provided in subsection (h), all Confidential Information of Licensee relating to the
Licensed Compound or any Licensed Product shall become Confidential Information of ArQule;

 

		(d)	except as provided in subsection (h), Licensee shall and hereby does, and shall cause its Affiliates
and its and their Sublicensees to, effective as of the effective date of termination, grant ArQule, a royalty-free exclusive license,
with the right to grant multiple tiers of sublicenses and further rights of reference, in and to: (i) the Licensee Patents, (ii)
Licensee Know-How, (iii) Licensee Inventions, (iv) Licensee Invention Patents, and (v) Licensee's rights in and to the Joint Patents
and Joint Inventions, to Exploit in the Territory any Licensed Compound or Licensed Product;

 

		(e)	except as provided in subsection (h) and unless expressly prohibited by any Regulatory Authority,
at ArQule's written request, Licensee shall, and shall cause its Affiliates and its and their Sublicensees to: (i) if ArQule notifies
Licensee of its intent to assume Control of ongoing clinical studies, transfer Control to ArQule of any or all clinical studies
involving Licensed Products being conducted by or on behalf of Licensee, an Affiliate or a Sublicensee as of the effective date
of termination and (ii) if ArQule does not notify Licensee of any intent to assume Control of ongoing clinical studies, promptly
wind down such studies in accordance with Applicable Law;

 

    	 	50	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(f)	except as provided in subsection (h), Licensee shall, and shall cause its Affiliates and its and
their Sublicensees to, provide a list to ArQule of all Licensed Product Agreements and assign to ArQule any Licensed Product Agreement
requested in writing by ArQule, unless, with respect to any such Licensed Product Agreement, such Licensed Product Agreement expressly
prohibits such assignment, in which case Licensee (or such Affiliate or Sublicensee, as applicable) shall co-operate with ArQule
in all reasonable respects to secure the consent of the applicable Third Party to such assignment, and if any such consent cannot
be obtained with respect to a Licensed Product Agreement, Licensee shall, and shall cause its Affiliates and its and their Sublicensees
to, obtain for ArQule substantially all of the practical benefit and burden under such Licensed Product Agreement, including by:
(i) entering into appropriate and reasonable alternative arrangements on terms agreeable to ArQule, and (ii) subject to the
consent and Control of ArQule, enforcing, at ArQule's cost and expense and for the account of ArQule, any and all rights of Licensee
(or such Affiliate or Sublicensee, as applicable) under such alternative arrangements, including any rights and remedies of Licensee
against the other party thereto arising out of the breach or cancellation thereof by such other party or otherwise;

 

		(g)	except as provided in subsection (h), at ArQule' written request, Licensee shall (i) supply ArQule
with such quantities of the Licensed Compound and Licensed Product in Licensee’s inventory on the effective date of termination
as may be requested by ArQule and (ii) supply to ArQule such additional quantities of the Licensed Compound and Licensed Products
as ArQule indicates in written forecasts and orders therefor from time to time, in any case, at Licensee's actual, fully-burdened
cost (plus ***%) to Manufacture such Licensed Compound and Licensed Products until the earlier of: (y) such time as ArQule
has established an alternate, validated source of supply for the Licensed Compound and Licensed Products, and ArQule is receiving
supply from such alternative source, and (z) the *** year anniversary of the effective date of termination of this Agreement;
and

 

		(h)	solely in the case of termination by Licensee for ArQule’s material breach, Licensee shall
have the right, by providing written notice to ArQule on or before the effective date of termination, to have the license granted
to Licensee in Clause 2.1 (Grants to Licensee) continue, subject to Licensee’s payment of all milestone and royalty payments
due and payable to ArQule in accordance with Clause 5 of this Agreement; provided that, the parties hereby agree that if Licensee
exercises the foregoing right to have such license continue, subsections (a) through (g) of this Clause 10.3 shall not apply.

 

		10.4	Remedies

 

Except as otherwise expressly
provided herein, termination of this Agreement (either in its entirety or with respect to one (1) or more country(ies)) in accordance
with the provisions hereof shall not limit remedies that may otherwise be available in law or equity.

 

		10.5	Accrued Rights; Surviving Obligations

 

Termination or expiration of
this Agreement (either in its entirety or with respect to one (1) or more country(ies)) for any reason shall be without prejudice
to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration
shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.
Without limiting the foregoing, Clauses 1 (DEFINITIONS), 2.1 (Grants to Licensee) (solely to the extent provided in Clause 10.3(h)
(Consequences of Termination)), 2.2 (Grants to ArQule) (except as provided in Clause 10.3 (Consequences of Termination)), 2.4(b)
(Rights of Reference) (except as provided in Clause 10.3 (Consequences of Termination)), 5.8 (Interest on Late Payments), 5.9 (Financial
Records), 5.10 (Audit), 5.11 (Audit Dispute), 6.1 (Ownership of Intellectual Property), 7 (CONFIDENTIALITY AND NON-DISCLOSURE),
9 (INDEMNITY; INSURANCE), 10.1 (Term and Expiration), 10.3 (Consequences of Termination), 10.4 (Remedies), 10.5 (Accrued Rights;
Surviving Obligations), and 11 (MISCELLANEOUS) of this Agreement shall survive the termination or expiration of this Agreement
for any reason.

 

    	 	51	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		11.	Miscellaneous

 

		11.1	Force Majeure

 

Neither Party shall be held liable
or responsible to the other Party or be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling
or performing any term of this Agreement (other than an obligation to make payments) when such failure or delay is caused by or
results from events beyond the reasonable Control of the non-performing Party, including fires, floods, earthquakes, hurricanes,
embargoes, shortages, epidemics, quarantines, war, acts of war (whether war be declared or not), terrorist acts, insurrections,
riots, civil commotion, strikes, lockouts or other labor disturbances (whether involving the workforce of the non-performing Party
or of any other Person), acts of God or acts, omissions or delays in acting by any governmental authority (including expropriation,
seizure of works, requisition, nationalization, and exercise of march-in rights or compulsory licensing, except to the extent such
delay results from the breach by the non-performing Party or any of its Affiliates of any term or condition of this Agreement).
The non-performing Party shall notify the other Party of such force majeure within thirty (30) days after such occurrence by giving
written notice to the other Party stating the nature of the event, its anticipated duration and any action being taken to avoid
or minimize its effect. The suspension of performance shall be of no greater scope and no longer duration than is necessary and
the non-performing Party shall use commercially reasonable efforts to remedy its inability to perform.

 

		11.2	Export Control

 

This Agreement is made subject
to any restrictions concerning the export of products or technical information from the United States or other countries that may
be imposed on the Parties from time to time. Each Party agrees that it will not export, directly or indirectly, any technical information
acquired from the other Party under this Agreement or any products using such technical information to a location or in a manner
that at the time of export requires an export license or other governmental approval, without first obtaining the written consent
to do so from the appropriate agency or other governmental entity in accordance with Applicable Law.

 

		11.3	Assignment

 

		(a)	Neither Party may assign its rights or, except as provided in Clause 3.6 (Subcontracting), delegate
its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part without the prior written consent
of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed, except that (i) Licensee shall have
the right, without such consent, to perform any or all of its obligations and exercise any or all of its rights under this Agreement
through any of its Affiliates, and (ii) either Party may assign any or all of its rights and delegate any or all of its obligations
hereunder to (1) any of its Affiliates (provided that no such assignment or delegation shall relieve the assigning or delegating
Party of any of its obligations or liabilities hereunder, for which obligations and liabilities such Party shall remain fully responsible
and liable) or (2) any Third Party successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or
substantially all of the business to which this Agreement relates; provided, that (y) such Party shall provide written notice
to the other Party of any assignment under this Section 11.3(a) within thirty (30) days after such assignment and (z) any Third
Party successor in interest of such assigning Party agrees in writing to be bound by the terms of this Agreement as if it were
the assigning Party, whereupon such Third Party successor in interest shall be deemed to be a party to this Agreement as though
named herein in substitution for the assigning Party. All validly assigned rights of a Party shall inure to the benefit of and
be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted
successors and assigns of such Party. Any attempted assignment or delegation in violation of this Clause 11.3 (Assignment) shall
be void and of no effect.

 

    	 	52	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		(b)	The rights to Information, materials and intellectual property:

 

		(i)	Controlled by a Third Party permitted assignee of a Party that immediately prior to such assignment
(other than as a result of a license or other grant of rights, covenant or assignment by such Party or its Affiliates to, or for
the benefit of, such Third Party); or

 

		(ii)	Controlled by an Affiliate of a Party that becomes an Affiliate through any Change of Control of
such Party that were Controlled by such Affiliate (and not such Party) immediately prior to such Change of Control (other than
as a result of a license or other grant of rights, covenant or assignment by such Party or its other Affiliates to, or for the
benefit of, such Affiliate), in each case ((a) and (b)), shall be automatically excluded from the rights licensed or granted to
the other Party under this Agreement.

 

		11.4	Severability

 

If any provision of this Agreement
is held to be illegal, invalid or unenforceable under any present or future law and if the rights or obligations of either Party
under this Agreement will not be materially and adversely affected thereby: (a) such provision shall be fully severable, (b) this
Agreement shall be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof,
(c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal,
invalid or unenforceable provision or by its severance herefrom, and (d) in lieu of such illegal, invalid or unenforceable
provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in
terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest
extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal,
invalid or unenforceable in any respect.

 

		11.5	Governing Law and Dispute Resolution

 

		(a)	This Agreement shall be governed by and construed in accordance with the laws of the State of
New York, USA, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation
of this Agreement to the substantive law of another jurisdiction.

 

		(b)	Except as provided in Clause 5.11 (Audit Dispute) or Clause 11.9 (Equitable Relief), if a
dispute arises:

 

		(i)	within the JDC with respect to any decision under the jurisdiction of the JDC (a JDC Dispute);
or

 

		(ii)	otherwise between the Parties in connection with or relating to this Agreement or any document
or instrument delivered in connection herewith (collectively, (i) and (ii), a Dispute),

 

then either
Party shall have the right to refer such Dispute to the Senior Officers for attempted resolution by good faith negotiations during
a period of ten (10) Business Days, which in the case of any Dispute that is not a JDC Dispute or involves a Unanimous Decision
(or would otherwise be subject to arbitration if unresolved) must include at least one (1) in-person meeting of the Senior Officers
(or his or her designee with authority to enter into a final resolution of such Dispute without the need to seek approval). Any
final decision mutually agreed to by the Senior Officers shall be conclusive and binding on the Parties.

 

    	 	53	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

(c)          If
such Senior Officers are unable to resolve any such Dispute that is a JDC Dispute within such *** Business Day period, then, unless
such Dispute involves a Unanimous Decision, the Parties shall refer such JDC Dispute to the chief executive officer of Licensee
for review and determination. The decision of the chief executive officer of Licensee shall be final, binding and conclusive. For
the avoidance of doubt, any Dispute related to Development strategy or operation of Licensed Product in the Territory shall be
a JDC Dispute and is subject to the final decision of the chief executive officer of Licensee; provided, that, if any such Dispute
involves a Unanimous Decision, such Dispute must be promptly resolved by consensus of the Senior Officers and may not be resolved
solely by the chief executive officer of Licensee nor submitted to arbitration for resolution.

 

(d)          If
such Senior Officers are unable to resolve any such Dispute that is not a JDC Dispute or relates to matters that involve a Unanimous
Decision within such *** Business Day period, either Party shall be free to institute binding arbitration in accordance with this
Clause 11.5 (Governing Law and Dispute Resolution) upon written notice to the other Party (an Arbitration Notice) and seek
such remedies as may be available. Upon receipt of an Arbitration Notice by a Party, the applicable Dispute shall be resolved by
final and binding arbitration before a panel of three (3) experts with relevant industry experience (the Arbitrators). Each
of Licensee and ArQule shall promptly select one (1) Arbitrator, which selections shall in no event be made later than *** days
after the notice of initiation of arbitration. The third Arbitrator shall be chosen promptly by mutual agreement of the Arbitrator
chosen by Licensee and the Arbitrator chosen by ArQule, but in no event later than *** days after the date that the last of such
Arbitrators was appointed. The Arbitrators shall determine what discovery will be permitted, consistent with the goal of reasonably
controlling the cost and time that the Parties must expend for discovery; provided that the Arbitrators shall permit such
discovery as they deem necessary to permit an equitable resolution of the Dispute. The arbitration shall be administered by the
American Arbitration Association (AAA) (or its successor entity) in accordance with the then-current Commercial Rules of
the AAA including the Procedures for Large, Complex Commercial Disputes (including the Optional Rules for Emergency Measures of
Protection), except as modified in this Agreement. The arbitration shall be held in New York City and shall be conducted in the
English language, and the Parties shall use reasonable efforts to expedite the arbitration if requested by either Party. The Arbitrators
shall, within *** days after the conclusion of the arbitration hearing, issue a written award and statement of decision describing
the essential findings and conclusions on which the award is based, including the calculation of any damages awarded. The written
award shall be selected from each Party’s proposal, and the Arbitrators will not have authority to impose any award not requested
by one of the Parties. The decision or award rendered by the Arbitrators shall be final, binding, conclusive and non-appealable,
and judgment may be entered upon it in accordance with Applicable Law in the State of New York or any other court of competent
jurisdiction. The Arbitrators shall be authorized to award compensatory damages, but shall not be authorized to reform, modify
or materially change this Agreement or any other agreements contemplated hereunder.

 

(e)          Each
Party shall bear its own counsel fees, costs, and disbursements arising out of the Dispute resolution procedures described in this
Clause 11.5 (Governing law and Dispute Resolution), and shall pay an equal share of the fees and costs of the Arbitrators, as applicable,
and all other general fees related to any arbitration described in Clause 11.5(c) or 11.5(d), as applicable; provided, however,
the Arbitrators shall be authorized to determine whether a Party is the prevailing Party, and if so, to award to that prevailing
Party reimbursement for its reasonable counsel fees, costs and disbursements (including expert witness fees and expenses, photocopy
charges, or travel expenses), or the fees and costs of the Arbitrators, as applicable. Unless the Parties otherwise agree in writing,
during the period of time that any arbitration proceeding described in Clause 11.5(c) or 11.5(d), as applicable, is pending under
this Agreement, the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject
of such pending arbitration proceeding. Nothing contained in this Agreement shall deny any Party the right to seek injunctive or
other equitable relief from a court of competent jurisdiction in the context of a bona fide emergency or prospective irreparable
harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration proceeding. All arbitration proceedings,
briefs, discovery and decisions and awards of the Arbitrator, under Clause 11.5(c) or Clause 11.5(d) as applicable, shall be deemed
Confidential Information of both Parties under Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE).

 

    	 	54	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

(f)          Each
Party further agrees that service of any process, summons, notice or document by registered mail to its address set forth in Clause 11.5
(Governing Law and Dispute Resolution) shall be effective service of process for any action, suit or proceeding brought against
it under this Agreement in any such court.

 

		11.6	Notices

 

		(a)	Notice Requirements

 

Any notice, request,
demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing,
shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile
transmission (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records
of delivery, addressed to the Parties at their respective addresses specified in paragraph (b) or to such other address
as the Party to whom notice is to be given may have provided to the other Party in accordance with this paragraph (a). Such
notice shall be deemed to have been given as of the date delivered by hand or transmitted by email (with delivery
confirmation and read receipt) or on the  second Business Day (at the place of delivery) after deposit with an
internationally recognized overnight delivery service. Any notice delivered by email shall be confirmed by a hard copy
delivered as soon as practicable thereafter. This Clause 11.6(a) (Notice Requirements) is not intended to govern the
day-to-day business communications necessary between the Parties in performing their obligations under the terms of this
Agreement.

 

		(b)	Address for Notice

 

If to Licensee, to:

 

Sinovant Sciences Ltd.

2 Church Street

Hamilton, Bermuda

Attention: Head, Global Transactions and Risk Management

Email:

 

with a copy (which shall not
constitute notice) to:

 

Roivant Sciences, Inc.

320 West 37th Street

5th Floor

New York, NY 10018

Attention: Legal Department

Email:

 

If to ArQule, to:

 

ArQule, Inc.

One Wall Street

Burlington, MA 01803

Attention: General Counsel

Tel: 781-994-0300

Fax: 781-376-6019

 

    	 	55	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

with a copy (which shall not
constitute notice) to:

 

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, MA 02111

Attention: John Cheney, Esq.

Tel: 617-542-6000

Fax: 617-542-2241

 

		11.7	Entire Agreement; Amendments

 

This Agreement, together with
the Schedules attached hereto, sets forth and constitutes the entire agreement and understanding between the Parties with respect
to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with
respect thereto are superseded hereby. Each Party confirms that it is not relying on any representations or warranties of the other
Party except as specifically set forth in this Agreement. No amendment, modification, release or discharge shall be binding on
the Parties unless in writing and duly executed by authorized representatives of both Parties. In the event of any inconsistencies
between this Agreement and any Schedules or other attachments hereto, the terms of this Agreement shall control.

 

		11.8	English Language

 

This Agreement shall be written
and executed in, and all other communications under or in connection with this Agreement shall be in, the English language. Any
translation into any other language shall not be an official version thereof and in the event of any conflict in interpretation
between the English version and such translation, the English version shall control.

 

		11.9	Equitable Relief

 

Each Party acknowledges and agrees
that the restrictions set forth in Clause 6 (INTELLECTUAL PROPERTY) and Clause 7 (CONFIDENTIALITY AND NON-DISCLOSURE) are
reasonable and necessary to protect the legitimate interests of the other Party and that such other Party would not have entered
into this Agreement in the absence of such restrictions and that any breach or threatened breach of any provision of such Clauses
may result in irreparable injury to such other Party for which there will be no adequate remedy at law. In the event of a breach
or threatened breach of any provision of such Clauses, the non-breaching Party shall be authorized and entitled to seek from any
court of competent jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting
of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other
rights or remedies to which such non-breaching Party may be entitled in law or equity. Both Parties agree to waive any requirement
that the other:

 

		(a)	post a bond or other security as a condition for obtaining any such relief; and

 

		(b)	show irreparable harm, balancing of harms, consideration of the public interest or inadequacy of
monetary damages as a remedy.

 

Nothing in
this Clause 11.9 (Equitable Relief) is intended, or should be construed, to limit either Party's right to equitable relief
or any other remedy for a breach of any other provision of this Agreement.

 

    	 	56	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		11.10	Waiver and Non-Exclusion of Remedies

 

Any term or condition of this
Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective
unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver
by either Party hereto of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed
a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise.
The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law
or otherwise available except as expressly set forth herein.

 

		11.11	No Benefit to Third Parties

 

Except as provided in Clause
9 (INDEMNITY; INSURANCE), covenants and agreements set forth in this Agreement are for the sole benefit of the Parties hereto and
their successors and permitted assigns and they shall not be construed as conferring any rights on any other Persons.

 

		11.12	Further Assurance

 

Each Party shall duly execute
and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts
and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other
Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof
or to better assure and confirm unto such other Party its rights and remedies under this Agreement.

 

		11.13	Relationship of the Parties

 

It is expressly agreed that ArQule,
on the one hand, and Licensee, on the other hand, shall be independent contractors and that the relationship between the two Parties
shall not constitute a partnership, joint venture or agency. Neither ArQule, on the one hand, nor Licensee, on the other hand,
shall have the authority to make any statements, representations or commitments of any kind or to take any action, that will be
binding on the other, without the prior written consent of the other Party to do so. All persons employed by a Party shall be employees
of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the
account and expense of such first Party.

 

		11.14	References

 

Unless otherwise specified: (a) references
in this Agreement to any Clause, Section or Schedule shall mean references to such Clause, Section or Schedule of this Agreement,
(b) references in any Section to any clause are references to such clause of such Section, and (c) references to any
agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed
or, if subsequently amended, replaced or supplemented from time to time, as so amended, replaced or supplemented and in effect
at the relevant time of reference thereto.

 

		11.15	Construction

 

Except where the context otherwise
requires, wherever used, the singular shall include the plural, the plural shall include the singular, the use of any gender shall
be applicable to all genders and the word "or" is used in the inclusive sense (and/or). Whenever this Agreement refers
to a number of days, unless otherwise specified, such number refers to calendar days. The captions of this Agreement are for convenience
of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision
contained in this Agreement. The term "including," "include," or "includes" as used herein shall
mean including, without limiting the generality of any description preceding such term. The language of this Agreement shall be
deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party
hereto.

 

    	 	57	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

		11.16	Counterparts

 

This Agreement may be executed
in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the
same instrument. This Agreement may be executed by PDF format via email or other electronically transmitted signatures and such
signatures shall be deemed to bind each Party hereto as if they were original signatures.

 

		11.17	Guaranty

 

In consideration of ArQule’s
entering into this Agreement, Parent hereby guarantees to ArQule the performance by Licensee of all of its financial obligations
under or arising out of the terms of this Agreement, including all indemnification obligations of Licensee under Section 9.1 (Indemnification
of ArQule) of this Agreement, the due and punctual payment of all financial obligations of Licensee and all payments to Third Parties
in connection with the Exploitation of the Licensed Compound and any Licensed Product, in each case after any applicable notice
and cure period requirements, until the earlier of the date that (a) Licensee completes an initial public offering of equity, (b)
Licensee completes a private financing of at least *** U.S. dollars ($***) or (c) a Change of Control transaction is consummated
in which Licensee is no longer an Affiliate of Parent. For clarity, Parent’s indemnification obligations shall terminate
absolutely upon the occurrence of any of subclause (a), (b) or (c) above, and Parent shall not be required to indemnify any Third
Party Claim that arises after such termination, regardless of when any Losses or facts comprising such Third Party Claim are alleged
to have occurred.

 

THIS AGREEMENT is executed by the
authorized representatives of the Parties as of the date first written above.

 

    	 	58	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Signatories

 

	ArQule, INC.	 	SINOVANT SCIENCES LTD.
	 	 	 	 	 
	By:	/s/ Peter S. Lawrence	 	By:	/s/ Marianne L. Romeo
	 	 	 	 	 
	Name: 	 Peter S. Lawrence	 	Name: 	Marianne L. Romeo
	 	 	 	 	 
	Title:	President and Chief Operating Officer	 	Title:	Head, Global Transactions & Risk Management

 

 

	 	Solely for the purpose of Clause 11.17 (Guaranty):  
	 	ROIVANT SCIENCES LTD.
	 	 	 
	 	By:	/s/ Marianne L. Romeo
	 	 	 
	 	Name: 	Marianne L. Romeo
	 	 	 
	 	Title:	Head, Global Transactions & Risk Management

 

    	 	59	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

 

Schedule
1

 

Existing
Patents

 

 

 

	ArQule Ref.	 	Status	 	Application No.	 	Application Date	 	Registration No.	 	Registration Date	 	Subject matter
	FGFR-AQ0142TW	 	Registered	 	098145881	 	12/30/2009	 	I461410	 	11/21/2014	 	CoM of ARQ 087
	FGFR-AQ0142US	 	Registered	 	12/649,573	 	12/30/2009	 	8,357,694	 	1/22/2013	 	CoM of ARQ 087
	FGFR-AQ0142AT	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142AU	 	Registered	 	2009335010	 	12/30/2009	 	2009335010	 	1/8/2015	 	CoM of ARQ 087
	FGFR-AQ0142BE	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142BR	 	Pending	 	PI0923786-0	 	12/30/2009	 	 	 	 	 	CoM of ARQ 087
	FGFR-AQ0142CA	 	Pending	 	2748491	 	12/30/2009	 	 	 	 	 	CoM of ARQ 087
	FGFR-AQ0142CH	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142CN	 	Registered	 	200980156889.X	 	12/30/2009	 	ZL200980156889.X	 	7/1/2015	 	CoM of ARQ 087
	FGFR-AQ0142DE	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142DK	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142EP	 	EP Granted	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142ES	 	Registered	 	ES2554623	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142FI	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142FR	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142GB	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142IE	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142IL	 	Registered	 	213787	 	12/30/2009	 	213787	 	12/1/2014	 	CoM of ARQ 087
	FGFR-AQ0142IN	 	Pending	 	2700/KOLNP/2011	 	12/30/2009	 	 	 	 	 	CoM of ARQ 087
	FGFR-AQ0142IT	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142JP	 	Registered	 	2011-544603	 	12/30/2009	 	5739820	 	5/1/2015	 	CoM of ARQ 087
	FGFR-AQ0142KR	 	Registered	 	10-2011-7017777	 	12/30/2009	 	1714799	 	3/3/2017	 	CoM of ARQ 087
	FGFR-AQ0142LU	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142MO	 	Registered	 	J/001849	 	12/30/2009	 	J/001849	 	12/14/2015	 	CoM of ARQ 087
	FGFR-AQ0142MX	 	Registered	 	MX/a/2011/006959	 	12/30/2009	 	309081	 	4/26/2013	 	CoM of ARQ 087
	FGFR-AQ0142NL	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142PH	 	Registered	 	1-2011-501340	 	12/30/2009	 	1/2011/501340	 	10/21/2014	 	CoM of ARQ 087
	FGFR-AQ0142SE	 	Registered	 	09793690.0	 	12/30/2009	 	2379506	 	9/2/2015	 	CoM of ARQ 087
	FGFR-AQ0142ZA	 	Registered	 	2011/04706	 	12/30/2009	 	2011/04706	 	8/29/2012	 	CoM of ARQ 087
	FGFR-AQ0196TW	 	Pending	 	105141873	 	12/16/2016	 	 	 	 	 	Solid form of ARQ 087
	FGFR-AQ0196US	 	Pending	 	15/381,414	 	12/16/2016	 	 	 	 	 	Solid form of ARQ 087
	FGFR-AQ0196PCT	 	Pending	 	PCT/US2016/067164	 	12/16/2016	 	 	 	 	 	Solid form of ARQ 087
	FGFR-AQ0197TW	 	Pending	 	105141874	 	12/16/2016	 	 	 	 	 	Method of making ARQ 087
	FGFR-AQ0197US	 	Registered	 	15/381,418	 	12/16/2016	 	9,834,519	 	12/5/2017	 	Method of making ARQ 087
	FGFR-AQ0197PCT	 	Pending	 	PCT/US2016/067161	 	12/16/2016	 	 	 	 	 	Method of making ARQ 087
	FGFR-AQ0197US DIV1	 	Pending	 	15/800,648	 	11/1/2017	 	 	 	 	 	Method of making ARQ 087

 

 

    	 	60	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

 

Schedule
2

 

Licensed
Compound

 

	Recommended International Nonproprietary Name (INN):	Derazantinib
	Company code	ARQ 087•2HCl
	The molecular formula	C29H29FN4O•2(HCl)
	Chemical Abstracts Service (CAS) registry number:	1821329-75-2
	IUPAC Name	(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-
5,6-dihydrobenzo[h]quinazolin-2-amine
	Structure	
        

         

 

    	 	61	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

  

Schedule
3

 

The
Initial Development Plan

 

Scope

 

The following document covers activities related to the Development
of Derazantinib in the Territory for the treatment of cancer. It outlines key activities in clinical (clinical development and
drug safety), biometrics and regulatory that will take place in the Territory, or will support the regulatory filings leading to
product Commercialization. These activities, to satisfy CFDA approval requirements in China and the approval requirements of other
regulatory agencies in the Territory, will be conducted under the direction of the JDC according to US standards of good clinical
practice (GCP) using GMP material. To the extent that this Development Plan differs or is inconsistent with the License Agreement,
the terms of the License Agreement shall govern.

 

In connection with this Initial Development Plan, Sinovant agrees
to conduct the clinical trials referenced below. The number of patients or subjects for each such trial represents Sinovant’s
best estimates at this time, and Sinovant agrees that it will increase the number of patients or subjects, as the case may be,
in each such trial to the extent reasonably necessary for approval of a trial by the CDFA or similar Regulatory Authority in the
Territory.

 

Sinovant shall conduct and bear the fully-loaded cost of an
approximately *** to be performed in China by Sinovant or its designee or subcontractor.

 

Sinovant also shall conduct and bear the fully-loaded cost of
an approximately *** to be performed in China by Sinovant or its designee or subcontractor. ***.

 

Plan Sinovant further shall conduct and bear the fully-loaded
cost of an approximately *** to be performed in China by Sinovant or its designee or subcontractor, such trial to be commenced
*** referenced above. ***.

 

Further clinical studies shall be discussed and agreed upon
by the JDC.

 

    	 	62	 

    Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 ***Triple asterisks denote omissions.

    

 

Schedule
4

 

ArQule
Know-How

 

ArQule Know-How is listed and contained in the ArQule dataroom.
Files in the dataroom containing ArQule Know-How include, but are not limited to, the following: ***

 

    	 	63

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]